UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 WASHINGTON,
D.C. 20549

 FORM 10-K

 (Mark
One)

 ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the fiscal year ended June 30, 2025

 or

 TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the transition period from ___________ to ___________

 Commission
File Number: 0-56615

COMPANY LIMITED

 (Exact
name of registrant as specified in its charter)

 Nevada

 37-2018431

 (State or other jurisdiction of

 (I.R.S. Employer

 incorporation or organization)

 Identification Number)

 G3-5-8016
Shui'an Town, Ruyi Headquarters Base

 Hohhot
Economic Development Zone

 Inner
Mongolia 010000

 P.R.
 China

 Office: +86 (0472) 510
4980

 (Address,
including zip code, and telephone number, including area code,

 of
Registrant's principal executive offices)

 Securities
registered pursuant to Section 12(b) of the Act:

 Title
 of Each Class

 Trading
 Symbol

 Name
 of Each Exchange on Which Registered

 None

 None

 Not Applicable

 Securities
registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value.

by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes No

by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes No

by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained
herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated
by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer,"
"smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 Large accelerated filer

 Accelerated filer

 Non-accelerated filer

 Smaller reporting company

 Emerging growth company

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.

 If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.

by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

by check mark whether the registrant is a shell company (as defined in Rule 12 b-2 of the Act). Yes No

 The
aggregate market value of the voting stock held by non-affiliates of the registrant at December 31, 2024, the last business day of the
registrant's most recently completed second fiscal quarter was $ 79,322,230 based on the last reported sales price of the registrant's
common stock as reported by the Nasdaq Stock Market on that date.

 As
of the date of filing of this report, there were outstanding 30,015,036 shares of the issuer's common stock, par value
$0.001 per share.

 DOCUMENTS
INCORPORATED BY REFERENCE

 List
hereunder the following documents if incorporated by reference and the Part of the Form 10-K (e.g., Part I, Part II, etc.) into which
the document is incorporated: (1) Any annual report to security holders; (2) Any proxy or information statement; and (3) Any prospectus
filed pursuant to Rule 424(b) or (c) under the Securities Act of 1933. The listed documents should be clearly described for identification
purposes (e.g., annual report to security holders for fiscal year ended December 24, 1980).

 None

 TABLE
OF CONTENTS

 Page

 Item
 1.

 Business

 Item
 1A.

 Risk Factors

 Item
 1B

 Unresolved Staff Comments

 Item
1C

 Cybersecurity

 Item
 2.

 Properties.

 Item
 3.

 Legal Proceedings.

 Item
 4.

 Mine Safety Disclosure

 Item
 5.

 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 Item
 6.

 [Reserved]

 Item
 7.

 Management's Discussion and Analysis of Financial Condition and Results of Operations.

 Item
 7A.

 Quantitative and Qualitative Disclosures About Market Risk.

 Item
 8.

 Financial Statements and Supplementary Data.

 Item
 9.

 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 Item
 9A.

 Controls and Procedures.

 Item
 9B.

 Other Information.

 Item
 9C

 Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

 Item
 10.

 Directors, Executive Officers, and Corporate Governance.

 Item
 11.

 Executive Compensation.

 Item
 12.

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 Item
 13.

 Certain Relationships and Related Transactions, and Director Independence.

 Item
 14.

 Principal Accountant Fees and Services.

 Item
 15.

 Exhibits, Financial Statement Schedules.

 Item

 Form 10-K Summary

 i

 PART
I

 Cautionary
Statement Regarding Forward Looking Statements

 The
discussion contained in this Annual Report on Form 10-K contains "forward-looking statements" within the meaning of Section
27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as
amended. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical
facts and may be forward-looking. These statements are often, but not always, made through the use of words or phrases like "anticipate,"
"estimate," "plans," "projects," "continuing," "ongoing," "target,"
"expects," "management believes," "we believe," "we intend," "we may," "we
will," "we should," "we seek," "we plan," the negative of those terms, and similar words or
phrases. We base these forward-looking statements on our expectations, assumptions, estimates and projections about our business and
the industry in which we operate as of the date of this Form 10-K. These forward-looking statements are subject to a number of risks
and uncertainties that cannot be predicted, quantified or controlled and that could cause actual results to differ materially from those
set forth in, contemplated by, or underlying the forward-looking statements. Statements in this Form 10-K describe factors, among
others, that could contribute to or cause these differences. Actual results may vary materially from those anticipated, estimated, projected
or expected should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect. Because
the factors discussed in this Form 10-K could cause actual results or outcomes to differ materially from those expressed in any forward-looking
statement made by us or on our behalf, you should not place undue reliance on any such forward-looking statement. New factors emerge
from time to time, and it is not possible for us to predict which will arise. In addition, we cannot assess the impact of each factor
on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those
contained in any forward-looking statement. Except as required by law, we undertake no obligation to publicly revise our forward-looking
statements to reflect events or circumstances that arise after the date of this Form 10-K.

 Item
1. Business

 Corporate
Structure

Company Limited ("Longduoduo") was incorporated in the State of Nevada on October 25, 2021. Longduoduo's principal
corporate address is G3-5-8016, Shui'an Town, Ruyi Headquarters Base, Hohhot Economic Development District, Hohhot, Inner Mongolia,
China, 010000. Our telephone number is +86 (0472) 510 4980. Our registered agent for service of process is Incorp Services, Inc., 3773
Howard Hughes Pkwy, Suite 500S, Las Vegas Nevada 89169-6014. Our website address is www.longduoduo.net. Our website and the information
contained on, or that can be accessed through, the website is not deemed to be incorporated by reference in, and is not considered part
of, this report, and the inclusion of our website address in this report is an inactive textual reference only. You should not rely on
any such information in making your decision whether to purchase our common stock.

IS A NEVADA CORPORATION THAT FUNCTIONS EXCLUSIVELY AS A HOLDING COMPANY. ALL OF THE BUSINESS OPERATIONS THAT ARE DESCRIBED IN THIS REPORT
AND REFLECTED IN THE FINANCIAL STATEMENTS CONTAINED IN THIS REPORT ARE CARRIED OUT BY SEVEN LIMITED COMPANIES ORGANIZED AND LOCATED IN
THE PEOPLE'S REPUBLIC OF CHINA ("PRC"). LONGDUODUO OWNS THE SEVEN OPERATING COMPANIES THROUGH AN INTERMEDIARY HOLDING
COMPANY REGISTERED IN HONG KONG.

 The
following chart describes our current corporate structure:

Company Limited (Hong Kong) ("Longduoduo HK"), was established on July 26, 2021 under the laws of Hong Kong. On
October 26, 2021, Longduoduo issued 30,000,000 shares of its common stock to the original shareholders of Longduoduo HK, in exchange
for 100% of the outstanding shares of Longduoduo HK.

 LDD
Technology Limited ("LDD") was established on March 18, 2024 under the laws of British Virgin Islands. On February 19, 2025,
Longduoduo issued 10,020 shares of its common stock to the original shareholders of LDD, in exchange for 100% of the outstanding shares
of LDD.

 LDDJK
Hong Kong Limited ("LDDJK") was established on April 9, 2024 under the laws of Hong Kong. LDD has controlled 100% of LDDJK
since its inception.

 Beijing
Julong Health Consulting Co., Limited ("Julong") was established in Beijing, China on July 23, 2024. LDDJK has controlled
100% of Julong since its inception.

 Beijing
Yihua Health Consulting Co., Limited ("Yihua") was established in Beijing, China on March 14, 2024. On January 7, 2025, Julong
acquired all the shares held by the original shareholders of Yihua, and controlled 100% ownership of Yihua.

Health Technology Company Limited ("Longduoduo Health Technology") is a privately held Limited Company, registered in Inner
Mongolia, China on August 20, 2020. On August 16, 2021, Longduoduo HK acquired 100% of Longduoduo Health Technology from the original
shareholders of Longduoduo Health Technology. On April 2, 2025, Julong acquired 100% of Longduoduo Health Technology from Longduoduo
HK.

 Inner
Mongolia Qingguo Health Consulting Company Limited ("Qingguo") is a privately held Limited Company, registered in Inner Mongolia,
China on June 18, 2020. On September 8, 2020, Longduoduo Health Technology acquired 90% of Qingguo from the original shareholders of
Qingguo.

 Inner
Mongolia Rongbin Health Consulting Company Limited ("Rongbin") is a privately held Limited Company, registered in Inner Mongolia,
China on March 18, 2021. Longduoduo Health Technology has controlled 80% of Rongbin since its inception.

 Inner
Mongolia Chengheng Health Consulting Company Limited ("Chengheng") is a privately held Limited Company, registered in Inner
Mongolia, China on April 9, 2021. Longduoduo Health Technology has controlled 80% of Chengheng since its inception.

 Inner
Mongolia Tianju Health Consulting Company Limited ("Tianju") is a privately held Limited Company registered in Inner Mongolia,
China on July 5, 2021. Longduoduo Health Technology has controlled 51% of Tianju since inception.

 Considerations
Relating to Regulation under Chinese Law

is not a Chinese operating company but a Nevada holding company with all of its operations conducted through seven subsidiaries located
in the PRC. Investors in the Company's common stock should be aware that they will not directly hold equity interests in a Chinese
operating entity, but rather are purchasing equity solely in a Nevada holding company that will be dependent upon distributions from
its principal Chinese subsidiary to finance the administrative expenses of the Nevada holding company and any cash distributions by the
Nevada holding company to its shareholders. Our ability to obtain contributions from the Company's subsidiary is significantly
affected by regulations promulgated by PRC authorities. Chinese regulatory authorities could prevent our principal Chinese subsidiary
from making distributions to its Nevada parent, which would likely result in a material change in our operations and cause the value
of our securities to significantly decline or become worthless. Any change in the interpretation by the PRC government of existing rules
and regulations or the promulgation of new rules and regulations may materially affect our operations or cause the value of our securities
to significantly decline or become worthless. For a detailed description of the risks facing the Company as a result of its dependence
on its Chinese operating subsidiaries, please refer to "Risk Factors - Risks Relating to Doing Business in the PRC."

 Exposure
to potential sanctions under the HFCAA

 Pursuant
to the Holding Foreign Companies Accountable Act ("HFCAA"), as adopted by the United States Congress in 2020, the Public
Company Accounting Oversight Board (the "PCAOB") issued a Determination Report on December 16, 2021 which found that the
PCAOB was unable to inspect or investigate completely registered public accounting firms headquartered in the PRC because of a position
taken by one or more authorities in mainland China. Under the HFCAA (as amended by the Consolidated Appropriations Act – 2023),
an issuer's securities may be prohibited from trading on a U.S. stock exchange or facility if its auditor is not inspected by the
PCAOB for two consecutive years (reduced by Congress in 2023 from three consecutive years in the original HFCAA).

 On
August 26, 2022, the China Securities Regulatory Commission ("CSRC"), the Ministry of Finance of China, and the PCAOB signed
a protocol governing inspections and investigations of audit firms based in China and Hong Kong. On December 15, 2022, the PCAOB
issued a new Determination Report which: (1) vacated the December 16, 2021 Determination Report; and (2) concluded that the PCAOB had
been able to conduct inspections and investigations completely in the PRC in 2022. The December 15, 2022 Determination Report cautions,
however, that authorities in the PRC might take positions at any time that would prevent the PCAOB from continuing to inspect or investigate
completely. As required by the HFCAA, if in the future the PCAOB determines it no longer can inspect or investigate completely because
of a position taken by an authority in the PRC, the PCAOB will act expeditiously to consider whether it should issue a new determination.
If the PCAOB is not able to fully conduct inspections of our auditor's work papers in the PRC, our securities may be prohibited
from trading on a U.S. stock exchange or facility if our auditor is not inspected by the PCAOB for two consecutive years, and this ultimately
could result in our common stock being barred from listing in the United States, which would likely prevent our shareholders from being
able to sell their shares until the bar was lifted.

recently engaged Bush & Associates CPA LLC as its independent auditor. Bush & Associates is headquartered in the State of Nevada.
The PCAOB is able to, and does, fully conduct inspections of our auditor's work papers. There remains a risk, however, that the
government of the PRC might in the future impose restrictions on the communication of information to auditors or by auditors of issuers
whose operations are located within the PRC, in such a way that investors in the securities of such issuers do not receive the full benefit
of the audits. In that situation, it could occur that the SEC would bar trading platforms subject to U.S. jurisdiction from listing Longduoduo's
securities for trading. Such an occurrence would be likely to cause the value of Longduoduo's securities to diminish significantly.

 Exposure
to restrictions on upstream distributions of profits

is a Nevada holding company with no business operations of its own. We conduct our operations in China through seven subsidiaries. We
will rely on dividends paid by our principal PRC subsidiary to fund the cash requirements of Longduoduo, including the funds necessary
to pay dividends and other cash distributions to our shareholders, to service any debt we may incur and to pay our operating expenses.
In order for us to pay dividends to our shareholders, we will rely on payments made from our principal PRC subsidiary to LDDJK Hong Kong
Limited ("LDDJK"). If Longduoduo is unable to receive profits from the operations of our PRC subsidiaries through LDDJK,
we will be unable to pay dividends on our common stock.

 The
PRC government also imposes controls on the conversion of RMB into foreign currencies and the remittance of currencies out of the PRC
through the Administrative Regulations of the PRC on Foreign Exchange (the "Foreign Exchange Regulations"), and the Notice
of State Administration of Foreign Exchange on Promulgation of the Provisions on Foreign Exchange Control on Direct Investments in China
by Foreign Investors. Therefore, we may experience difficulties in completing the administrative procedures necessary to obtain and remit
foreign currency for the payment of dividends from our profits, if any. The Foreign Exchange Regulations will present a barrier to currency
transactions between our U.S. parent company and our Chinese operating subsidiary. If we raise funds in the U.S. dollars for the purpose
of funding our operations in China, we will be required to obtain SAFE approval of the conversion of the dollars into Renminbi, which
could be denied.

 Current
PRC regulations permit Longduoduo's PRC subsidiaries to pay dividends to Longduoduo and its Hong Kong subsidiary only out of their
accumulated profits, if any, determined in accordance with Chinese accounting standards and regulations. In addition, each of our subsidiaries
in China is required to set aside at least 10% of its after-tax profits each year to fund a statutory reserve until such reserve reaches
50% of its registered capital. Our subsidiaries in China are also required to further set aside a portion of their after-tax profits
to fund their employee welfare fund, although the amount to be set aside, if any, is determined at the discretion of the subsidiary's
board of directors. Although the statutory reserves can be used, among other ways, to increase the registered capital and eliminate future
losses in excess of retained earnings of the PRC subsidiary, the reserve funds are not distributable as cash dividends except in the
event of liquidation. If one or more of our PRC subsidiaries incurs debt on its own behalf in the future, the instruments governing the
debt may restrict its ability to pay dividends or make other distributions to us.

 If
Longduoduo is considered a PRC tax resident enterprise for tax purposes, any dividends its pays to our shareholders may be regarded as
China-sourced income and, as a result, may be subject to PRC withholding tax at a rate of up to 10.0%. Certain payments from Julong,
our principal PRC subsidiary, to LDDJK are subject to PRC taxes. As of the date of this Report, Julong has not made any transfers or
distributions.

 Pursuant
to the Arrangement between Mainland China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Tax
Evasion on Income, or the "Double Tax Avoidance Arrangement," the 10% withholding tax rate may be lowered to 5% if a Hong
Kong resident enterprise owns no less than 25% of the PRC entity during the 12 consecutive months preceding its receipt of the dividends.
In current practice, a Hong Kong entity must obtain a tax resident certificate from the Hong Kong tax authority to apply for the 5% lower
PRC withholding tax rate. As the Hong Kong tax authority will issue such a tax resident certificate on a case-by-case basis, we cannot
assure you that we will be able to obtain the tax resident certificate from the relevant Hong Kong tax authority and enjoy the preferential
withholding tax rate of 5% under the Double Taxation Arrangement with respect to dividends to be paid by Julong to its immediate holding
company, LDDJK. As of the date of this Report, Julong does not plan to declare and pay dividends to LDDJK and we have not applied for
the tax resident certificate from the relevant Hong Kong tax authority.

 At
the date of this Report, no subsidiary of Longduoduo has paid any dividend or distribution to Longduoduo or any subsidiary of Longduoduo,
nor has Longduoduo made any dividend or distribution to any U.S. investor. There has been no transfer of cash or other assets between
or among Longduoduo, LDDJK and/or any Chinese subsidiary of Longduoduo.

 PRC
Government Oversight

in China's internal regulatory mandates, such as the M&A rules, Anti-Monopoly Law, and the Data Security Law, may target the
Company's corporate structure and impact our ability to conduct business in China, accept foreign investments, or list on a U.S.
or other foreign exchange. Recently, the PRC government initiated a series of regulatory actions affecting business operations in China
with little advance notice, including banning certain activities in the securities market, enhancing supervision over China-based companies
listed overseas using variable interest entity structure, adopting new measures to extend the scope of cybersecurity reviews, and expanding
its efforts in anti-monopoly enforcement. The business of our subsidiaries until now has not been subject to cybersecurity review with
the Cyberspace Administration of China, or CAC, given that: (i) data processed in our business does not have a bearing on national security
and thus may not be classified as core or important data by the authorities; (ii) we have not yet approached the regulatory thresholds
for holding personal information in our business operations. In addition, we are not subject to merger control review by China's
anti-monopoly enforcement agency due to the level of our revenues and the fact that we currently do not expect to propose or implement
any acquisition of control of, or decisive influence over, any company with revenues within China of more than RMB400 million. However,
since these regulatory actions are new, it is uncertain how soon legislative or administrative regulation making bodies will respond
and what existing or new laws or regulations or detailed implementations and interpretations will be modified or promulgated, and the
potential impact such modified or new laws and regulations will have on our daily business operation, our ability to accept foreign investments
and our ability to list our securities on an U.S. or other foreign exchange.

 We
intend to fund the growth of our business in large part by raising capital in Longduoduo through its sale of securities outside of the
PRC. The capital markets in the U.S. that we might access for financing will depend in large part on our ability to secure a listing
on Nasdaq, OTCQX or one of the registered securities exchanges. The Trial Administrative Measures adopted by the China Securities Regulatory
Commission ("CSRC") on March 31, 2023 require that at the time we apply to an exchange (which for this purpose will include
Nasdaq, OTCQB or OTCQX), we must file an extensive application with the CSRC and await approval by CSRC of the listing. The CSRC has
indicated an intent to use these applications in order to protect the PRC from foreign control of (or significant influence over) important
Chinese businesses. We cannot determine what criteria the CSRC will apply for this purpose. The regulations, therefore, create for our
investors a risk that our efforts to finance Julong by selling Longduoduo securities abroad will be restricted, delayed or eliminated
by CSRC's implementation of the listing requirements in the Trial Administrative Measures. That risk, if realized, could prevent
us from expanding business of Longduoduo's chinese subsidiary, which could reduce or eliminate the value of Longduoduo common stock.

 Summary
of Additional Risk Factors Pertaining to Operations in China

 There
are additional risks associated with our operations being in the PRC. The following summarizes certain additional risk factors that are
discussed in detail in the section titled "Risk Factors: Risks related to Doing Business in the PRC at page 17 et seq.

in United States and China relations, as well as relations with other countries, and/or regulations may adversely impact our business,
our operating results, our ability to raise capital and the market price of our shares. As a U.S.-listed public company, we may
face heightened scrutiny, criticism and negative publicity in the PRC, which could result in a material change in our operations and
the value of our common stock.

 Uncertainties
with respect to the PRC legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in
laws and regulations in China could adversely affect us and limit the legal protections available to your and us. The dramatic
growth of China and rapid changes in government policies since the 1980s cause change in the legal system that make compliance difficult
and policies unpredictable.

 Because
our principal assets are located outside of the United States and because all of our directors and all our officers reside outside of
the United States, it may be difficult for you to use the United States Federal securities laws to enforce your rights against us and
our officers or to enforce judgments of United States courts against us or them in the PRC.

 The
fluctuation of RMB may materially and adversely affect your investment. If the Chinese government reduces the relative value
of the RMB compared to the U.S. Dollar, the value in Dollars of the Company will decline.

 We
may become subject to a variety of laws and regulations in the PRC regarding privacy, data security, cybersecutiry, and data protection.
We may be liable for improper use or appropriation of personal information provided by our customers.

 If
Longduoduo common stock becomes listed on the OTCQB or an exchange, we will be required to obtain the approval of the PRC government
for a business combination, the issuance of our common stock, or maintaining our status as a publicly listed company outside China.

 Our
Business

 Our
operating subsidiaries, Julong, Longduoduo Health Technology, Qingguo, Rongbin, Chengheng, Tianju and Yihua, serve, for some customers,
as sales agents for third-party healthcare service providers and, for other customers, as distributors of services provided by third-party
healthcare service providers. In both arrangements, the health care providers provide comprehensive and high-quality preventive healthcare
solutions, including disease screening, healthcare treatments, healthcare products and other services. The Company mainly focuses on
prevention of myocardial infarction, cerebral infarction, hemiplegia, and cardiovascular and cerebrovascular diseases.

 Commissioned
Sales

 Since
June of 2023, our operating subsidiaries have been primarily engaged in selling health maintenance services provided by Inner Mongolia
Honghai Health Management Co., Ltd. ("Honghai"). During the year ended June 30, 2025, over 97% of our gross revenue came
from commissions earned through our agency relationship with Honghai. Each operating subsidiary is party to a separate Sales Agency Agreement
with Honghai, each dated June 20, 2023 and expiring on June 20, 2026, although the content of the five Sales Agency Agreements are identical
but for the name of the agent: Longduoduo Health Technology Co., Ltd, Inner Mongolia Rongbin Health Consulting Co., Ltd, Inner Mongolia
Chengheng Health Consulting Co., Ltd, Inner Mongolia Qinguo Health Consulting Co., Ltd. or Inner Mongolia Tianju Health Consulting Company
Limited. Among the principal terms of the Sales Agency Agreements are:

 Honghai
is responsible for developing and providing services, and our operating subsidiary (the "Agent") is responsible for promoting
and selling the services.

 When
the Sales Agency Agreement was signed, the specific services to be marketed were: trioxygen autotransfusion, awakening brain and dredging
collaterals, double blood purification in German technology, hyperbaric trioxygen, colon hydrotherapy, intestinal flora transplantation,
custom-made Juncao and combinations of these services.

 If
Honghai develops new services, the Agent will have the option to market the new services at a price to be negotiated with Honghai in
accordance with criteria set in the Sales Agency Agreement.

 The
Agent is responsible for collecting payment on each sale, and forwarding the payment to Honghai net of the pre-approved settlement amount
– i.e. commission.

 Honghai
bears all responsibility for the quality of the services and for any liability to customers arising from the services.

 Principal
Sales

 Before
we entered the Sales Agency Agreements with Honghai, our operating subsidiaries marketed healthcare services and products exclusively
as principals, by purchasing and reselling services and products from third-party healthcare service providers such as hospitals to serve
customers located in Hohhot, Ordos, Baotou and Ulanqab, cities in Inner Mongolia. We continue that business, although "service
revenue" from these principal sales fell by almost 63% in the year ended June 30, 2025 from the service revenue recorded in the
year ended June 30, 2024. Our intention, after we have built a firm foundation for our agency sales business, is to return our attention
to principal sales and build a network of third-party healthcare service providers, product suppliers and our sales agents so that we
can offer a broader array of products and services to potential customers.

 Currently,
working with our third-party healthcare service providers, our operating subsidiaries provide, as principal, the preventive healthcare
solutions including below:

 Meridian-regulating and
 Consciousness-restoring Iatrotechnics- a traditional Chinese medicine treatment that is anti-thrombotic to prevent and treat cardiovascular
 and cerebrovascular diseases.

 Double Blood Purification
 – treatment for cardiovascular and cerebrovascular diseases that involves the removal of pathogens and toxins from the blood
 through physical means such as filtration.

 Immunological Ozonated
 Autohemotherapy; the Third-generation Ozone Therapy Device – Autologous Blood Immunotherapy - prevention and treatment of cardiovascular
 and cerebrovascular diseases relying on the use of an ozone therapy device to remove pathogens and toxins from the blood.

 PRP (platelet-rich plasma)
 – prevention and treatment of joint inflammation and injury through the use of platelet rich plasma.

 Relaxation therapy - a
 traditional Chinese medicine treatment that is used to treat joint function limitation caused by soft tissue adhesion such as periarthritis
 of shoulder.

 Vegetative Nerve Regulation
 - a treatment for neck, shoulder, back and leg pain.

 Microwave Therapy –
 through the use of specific equipment, heat is provided deep into the skin to reduce inflammation, detumescence, relieve pain and
 improve tissue blood circulation, prevent and cure lumbar muscle strain, arthritis, periarthritis of shoulders and other diseases.

 All
medical services above are provided by healthcare service providers that are licensed medical institutions, such as hospitals or medical
clinics. These medical services are provided directly to our customer by our healthcare service providers, and our healthcare service
providers bear the risk of liability related to the medical procedures.

 Our
operating subsidiaries have contracted with four third-party healthcare service providers. The contracts are set out below:

 Cooperation Agreement,
 dated March 26, 2021 and expiring on March 31, 2026, by and between Inner Mongolia Qinguo Health Consulting Co., Ltd. and Hohhot
 Aihua Traditional Chinese Medicine Hospital, which is located in Hohhot. Under the terms of this agreement, Hohhot Aihua Traditional
 Chinese Medicine Hospital offers services such as "Immunological Ozonated Autohemotherapy", "Meridian-regulating
 and Consciousness-restoring Iatrotechnics", "PRP", "Relaxation therapy", "Vegetative Nerve Regulation
 (anterior)" and other conventional therapies.

 Leasing and Cooperation
 Agreement, dated October 15, 2020 and expiring on October 15, 2025, by and between Longduoduo Health Technology Co., Ltd and Baotou
 Jinshi Zhongyi Nephropathy Hospital, which is located in Baotou. Under the terms of this agreement, Baotou Jinshi Zhongyi Nephropathy
 Hospital offers services such as "Meridian-regulating and Consciousness-restoring Iatrotechnics", "Double Blood
 Purification" and "Immunological Ozonated Autohemotherapy".

 Cooperation Agreement,
 dated November 18, 2024 and expiring on November 18, 2027, by and between Inner Mongolia Chengheng Health Consulting Co., Ltd and
 Inner Mongolia Jiuzun Health Examination Co., Ltd, which located in Ordos. Under the terms of this agreement, Zhongyi Hospital Branch
 of Inner Mongolia Jiuzun Health Examination Co., Ltd offers customers of Chengheng services such as "the Third-generation Ozone
 Therapy Device – Autologous Blood Immunotherapy".

 Cooperation Agreement,
 dated June 20, 2021 and expiring on June 19, 2026, by and between Longduoduo Health Technology Co., Ltd and Ulanqab Mengzhong Rehabilitation
 TCM Hospital Co., Ltd, which is located in Ulanqab. Under the terms of this agreement, Ulanqab Mengzhong Rehabilitation TCM Hospital
 Co., Ltd offers services such as "Immunological Ozonated Autohemotherapy", "Meridian-regulating and Consciousness-restoring
 Iatrotechnics", "PRP", "Relaxation therapy", "Vegetative Nerve Regulation" and other conventional
 therapies.

 Our
operating subsidiaries pay service fees to these third-party healthcare service providers based on the number of health products, medical
examinations and the services they provide for our customers. We carefully select our third-party healthcare service provider based on
our internal assessment of the quality of the provider's institution and staff. We assess potential third-party healthcare service
providers and chose future third-party healthcare service providers that fit our business based on the following points:

 Quality
of Services – including required and complementary services, the quality of the venue, as well as the quality of management, medicines,
consumables etc;

 Location:
whether the venue is convenient for our customers.

 Price:
whether the medical examination and treatment price is acceptable.

 Reputation:
whether the providers have a good reputation.

 Equipment:
whether the provider possess advanced medical equipment.

 Our
Plan for Growth

 In
the long run, by leveraging our growing network of medical centers, large and loyal customer base, established demographic and disease
information database, we plan to expand the scope of our service offerings and ultimately establish our company as a leading health management
service provider and sales agency in China. We intend to achieve our goal by implementing the following strategies:

 further
expanding our product offerings;

 continuing
to expand our network coverage nationwide; and

 further
upgrading our service standards to enhance the customer experience.

 The
successful execution of our business plan is subject to risks and uncertainties related to our business and industry, including those
relating to our ability to:

 maintain
and enhance the recognition and reputation of our operating subsidiaries;

 compete
effectively;

 manage
our growth and execute our strategies effectively;

 provide
superior customer experience and offer services at attractive prices to meet customer needs and preferences;

 manage
and expand our relationships with suppliers and third-party service providers; and

 secure
and retain the services of qualified personnel.

 We
face significant competition from two main types of competitors: the medical examination departments of major public hospitals and private
medical examination companies. Some of our current or future competitors may have longer operating histories, greater brand recognition,
better supplier relationships, larger customer bases or greater financial, technical or marketing resources than we do. There is no assurance
that we will be able to successfully compete against these larger and better funded competitors.

 Our
performance will be largely dependent on the talents and efforts of highly skilled individuals. Future success depends on our continuing
ability to identify, hire, develop, motivate and retain highly qualified personnel for all areas of our organization. Competition for
such qualified employees is intense. If we do not succeed in attracting excellent personnel or in retaining or motivating them, we may
be unable to grow effectively.

 We
rely on our third-party healthcare service providers to provide services to our customers under cooperation arrangements with us. We
require and expect these third-party healthcare service providers to possess the licenses and qualifications that are required for their
operations and to adhere to certain performance standards both in terms of customer service and the quality of the medical care that
they provide. We generally do not have control over the quality of service or medical care that these third-parties provide. They may
not at all times possess the permits or qualifications required by laws and regulations or may fail to meet other regulatory requirements
for their operations. In addition, they may engage in conduct which our customers find unacceptable, including providing poor service,
mishandling sensitive personal healthcare information or committing medical malpractice.

 Operating
Licenses

 Our
products and services are subject to regulation by governmental agencies in the PRC and Inner Mongolia Province. Business and company
registrations are certified on a regular basis and must be in compliance with the laws and regulations of the PRC and provincial and
local governments and industry agencies, which are controlled and monitored through the issuance of licenses. Our licenses include:

Health Technology's operating license enables it to undertake medical information consulting services, corporate management consulting,
health management consulting services and so on. The registration number is 91150104MA0QTDXG5T, which is valid from August 20, 2020,
and expires on August 19, 2050.

 Qingguo's
operating license enables it to undertake sales of food, health management consulting services, and medical information consulting services.
The registration number is 91150104MA13Q5X152, which is valid from June 18, 2020, with no expiration date.

 Rongbin's
operating license enables it to undertake medical information consulting services, corporate management consulting, and health management
consulting services. The registration number is 91150207MA13UKC301, which is valid from March 18, 2021, and expires on March 17, 2051.

 Chengheng's
operating license enables it to undertake medical information consulting services, corporate management consulting, and health management
consulting services. The registration number is 91150602MA7YN4JE2Q, which is valid from April 09, 2021, and expires on April 08, 2051.

 Tianju's operating
 license enables it to undertake sales of class I medical equipment, pre-packaged food, hygiene products, cosmetics, and disinfection
 products; health management consulting services; medical information consulting services; software development; biotechnology promotion
 services; beauty services (excluding medical beauty), technical services, and technology Consultation; leasing of medical equipment.
 The registration number is 91150902MA7YPWL408, which is valid from July 5, 2021 to July 4, 2051.

 Julong's Business
 License enables us to undertake health management consulting services (excluding medical services) and other related services. The
 registration number is 91110112MADR3N7X9U, which is valid from July 23, 2024, with no expiration date.

 Yihua's Business
 License enables us to undertake health management consulting services (excluding medical services) and other related services. The
 registration number is 91110112MADEPYKMXX, which is valid from March 14, 2024, with no expiration date.

 The
PRC legal system is based on written statutes. Prior court decisions may be cited for reference but have limited precedential value.
In 1979, the PRC government began to promulgate a comprehensive system of laws and regulations governing economic matters in general,
such as foreign investment, corporate organization and governance, commerce, taxation and trade. However, since the PRC legal system
continues to evolve rapidly, the interpretations of many laws, regulations and rules are not always uniform and enforcement of these
laws, regulations and rules involves uncertainties, which may limit legal protections available to us. Uncertainties due to evolving
laws and regulations could also impede the ability of a China-based company, such as Longduoduo Health Technology, to obtain or maintain
permits or licenses required to conduct business in China. In the absence of required permits or licenses, governmental authorities could
impose material sanctions or penalties on us or could revoke our authority to carry on business. In addition, some regulatory requirements
issued by certain PRC government authorities may not be consistently applied by other PRC government authorities (including local government
authorities), thus making strict compliance with all regulatory requirements impractical, or in some circumstances impossible.

 Competition

 We
face significant competition from two main types of competitors: the medical examination departments of major public hospitals and private
medical examination companies. The private medical examination market is further segmented into (i) large national companies; (ii) regional
providers; (iii) numerous local independent medical examination centers located in nearly every city in China; and other sales agencies
of health services.

 We
believe our primary competitive advantages over our competitors include:

 strong
sales and marketing efforts;

 our
innovative approach to the health care market; and

 Our
flexible management mechanism.

 We
believe that we are well-positioned to effectively compete on the basis of the factors listed above. However, some of our current or
future competitors may have longer operating histories, greater brand recognition, better supplier relationships, larger customer bases
or greater financial, technical or marketing resources than we do. There is no assurance that we will be able to successfully compete
against these larger and better funded competitors.

 Income
Taxes

 United
States

Company Limited is subject to a tax rate of 21% in the United States of America.

 Hong
Kong

HK and LDDJK were incorporated in Hong Kong and is subject to Hong Kong profits tax. They are subject to Hong Kong taxation on its
activities conducted in Hong Kong and income arising in or derived from Hong Kong. The applicable statutory tax rate is 16.5%. The
Company has not had any income (loss) subject to the Hong Kong profits tax.

 China

 Julong
and its subsidiaries are subject to a 25% standard enterprise income tax in the PRC. The Company accrued $222,268 and $523,207 of PRC
income tax for the years ended June 30, 2025 and 2024.

 Employees

 The
Company has 52 full-time employees. Of those 49, Qingguo has 10 full-time employees, Rongbin has 14 full-time employees, Chengheng has
6 full-time employees, Tianju has 6 full-time employees and Longduoduo Health Technology has 16 full-time employees.

 The
Company's employees include 10 with management responsibilities, 19 with administrative and operations responsibilities, and 23
responsible for customer services.

 All
of our employees are located in the PRC. None of our employees are represented by a labor union or similar collective bargaining organization.

 Item
1A. Risk Factors.

 An
investment in our common stock involves a high degree of risk. You should carefully consider the following risk factors and other information
in this 10K before deciding to invest in our Company. If any of the following risks actually occur, our business, financial condition
and results of operations could be seriously harmed. As a result, the trading price of our common stock could decline and you could lose
all or part of your investment.

 Risks
Related to Our Business

 97%
of our revenue during the year ended June 30, 2025 came from a single source: Inner Mongolia Honghai Health Management Co., Ltd. Termination
of our relationship with Honghai would likely have serious adverse effects on our financial results.

 In
June 2023 each of our operating subsidiaries entered into identical Sales Agency Agreements with Inner Mongolia Honghai Health Management
Co., Ltd. ("Honghai"), pursuant to which our operating subsidiaries serve as sales agents for services provided by Honghai
and receive commissions on the sales they initiate. During the year ended June 30, 2025, commissions from sales on behalf of Honghai
represented over 97% of our Company's revenues, while revenues from principal sales, our focus before engaging with Honghai, fell
by almost 63%.

 The
Sales Agency Agreements terminate in June 2026, and there is no certainty that our relationship with Honghai will continue past that
date In addition, any number of factors could interfere with our relationship with Honghai: adverse events in Honghai's business
could make our sales efforts unprofitable; Honghai could decide to engage competitive or replacement sales agents; licensing problems
or adverse government regulation could interfere with Honghai's business or our ability to market Honghai's services. In
the event that any of these risks was realized, our financial results could be significantly less profitable unless and until we were
able to replace Honghai as the primary source of our revenue.

 We
rely on third party providers to provide our offered services and could be liable and suffer reputational harm if a third-party service
provider provides inferior service or harms a customer, which may have a material adverse effect on our business, financial condition,
results of operations and prospects.

 We
rely on our third-party healthcare service providers to provide services to our customers under cooperation arrangements with us. We
require and expect these third-party healthcare service providers to possess the licenses and qualifications that are required for their
operations and to adhere to certain performance standards both in terms of customer service and the quality of the medical care that
they provide. We generally do not have control over the quality of service or medical care that these third-parties provide. They may
not at all times possess the permits or qualifications required by laws and regulations or may fail to meet other regulatory requirements
for their operations. In addition, they may engage in conduct which our customers find unacceptable, including providing poor service,
mishandling sensitive personal healthcare information and committing medical malpractice. We could be exposed to reputational harm and
possible liability as a result of our having serviced a customer through a third-party service provider that performs unsatisfactorily,
which may result in a materially adverse effect on our business, financial condition, results of operations and prospects.

 A
computer system failure, security breach or a breach of data privacy or security obligations may disrupt our business, damage our reputation
and adversely affect our results of operations, financial condition and cash flows.

 We
rely on computer and information systems and internet and network connectivity to conduct a large portion of our business operations.
This includes the need to securely store, process and transmit confidential information, including personal information. In many cases
this also includes transmission and processing to or through commercial customers, business partners and third-party service providers.
The introduction of new technologies, computer system failures, cyber-crime attacks or security or privacy breaches may materially disrupt
our business operations, damage our reputation, result in regulatory and litigation exposure, investigation and remediation costs, and
materially and adversely affect our results of operations, financial condition and cash flows.

 The
information security risk that we face includes the risk of malicious outside forces using public networks and other methods, including
social engineering and the exploitation of targeted offline processes, to attack our systems and information. It also includes inside
threats, both malicious and accidental. For example, human error and lack of sufficiently automated processing can result in improper
information exposure or use. We also face risk in this area due to our reliance in many cases on third-party systems, all of which may
face cyber and information security risks of their own. Third-party administrators or distribution partners used by us or our subsidiaries
may not adequately secure their own information systems and networks, or may not adequately keep pace with the dynamic changes in this
area. Potential bad actors that target us and our applicable third parties may include, but are not limited to, criminal organizations,
foreign government bodies, political factions, and others. There is no guarantee that the measures that we take will be sufficient to
stop all types of attacks or mitigate all types of information security or privacy risks.

 If
we fail to maintain adequate processes and controls or if we or our business partners fail to comply with relevant laws and regulations,
policies and procedures, misappropriation or intentional or unintentional inappropriate disclosure or misuse of personal information
or other confidential information could occur. Such control inadequacies or non-compliance could cause disrupted operations and misstated
or unreliable financial data, materially damage our reputation or lead to increased regulatory scrutiny or civil or criminal penalties
or litigation, which, in turn, could have a material adverse effect on our business, financial condition and results of operations. In
addition, we analyse personal information and customer data to better manage our business, subject to applicable laws and regulations
and other restrictions. It is possible that additional regulatory or other restrictions regarding the use of such techniques may be imposed.
Such restrictions and obligations could have material impacts on our business, financial conditions and/or results of operations.

 We
operate in a competitive environment and competing facilities and services could harm our business, financial condition, results of operations
and prospects.

 There
are numerous hospitals and private clinics providing medical examination services and, at the high end of the market, many Chinese hospitals
have VIP wards that cater to affluent customers. We face significant competition from two main types of competitors: the medical examination
departments of major public hospitals and private medical examination companies. The private preventive healthcare market is further
segmented into large franchise companies, regional providers and numerous local independent medical examination centers located in nearly
every city in China. We compete primarily on the basis of price, quality of service, convenience, location, brand recognition and reputation.
We do not have the same level of brand recognition as some of the medical examination centers of large public hospitals, and in some
regional markets our brand is not as established and our geographical coverage is not as extensive as that of our private competitors.
Furthermore, we lack the equipment necessary for certain highly technical medical tests. Many competing hospitals that are government-owned
are exempt from income taxes on their medical income, which provides them with a significant competitive advantage over us. Furthermore,
competing hospitals, clinics or other facilities may commence new operations or expand existing operations, which would increase their
competitive position and potentially erode our business, financial condition, results of operations and prospects.

 We
may not be able to effectively control and manage our planned growth.

 We
have limited operational, administrative and financial resources, which may be inadequate to sustain the growth we want to achieve. If
our business and markets grow and develop, it will be necessary for us to finance and manage expansion accordingly. In addition, we may
face challenges in managing our expanding service offerings. Such growth would place increased demands on our existing management, employees
and facilities. Our failure to meet these demands could interrupt or adversely affect our operations and cause administrative inefficiencies.
Additionally, failure to execute our planned growth strategy could have a material adverse effect on our financial condition and results
of operation.

 Expansion
of our healthcare services could be affected by the expansion of government-sponsored social medical insurance available to the Chinese
population that is not available now.

 Most
government-sponsored social medical insurance in China does not cover medical examinations. In certain locations where government-sponsored
social medical insurance covers medical examinations, we have cooperating hospitals that are qualified institutions under such insurance
coverage. Currently, most of our individual customers pay directly for medical examinations. If government-sponsored social medical insurance
is further expanded to cover medical examinations in more geographical locations, and Longduoduo does not become a qualified institution
for such coverage, certain of our customers may discontinue or terminate their relationship with us, and certain individual customers
may opt to use other medical institutions covered by such medical insurance rather than pay for our services. As a result, the expansion
of government-sponsored social medical insurance could materially and adversely affect our business, financial condition and results
of operations.

 Additional
capital, if needed, may not be available on acceptable terms, if at all, and any additional financing may be on terms adverse to your
interests.

 We
may need additional cash to fund our operations. Our capital needs will depend on numerous factors, including market conditions and our
profitability. We cannot be certain that we will be able to obtain additional financing on favorable terms, if at all. If additional
financing is not available when required or is not available on acceptable terms, we may be unable to fund expansion, successfully promote
our brand name, develop or enhance our services, take advantage of business opportunities, or respond to competitive pressures or unanticipated
requirements, any of which could seriously harm our business and reduce the value of your investment.

 If
we are able to raise additional funds if and when needed by issuing additional equity securities, you may experience significant dilution
of your ownership interest and holders of these new securities may have rights senior to yours as a holder of our common stock. If we
obtain additional financing by issuing debt securities, the terms of those securities could restrict or prevent us from declaring dividends
and could limit our flexibility in making business decisions. In this case, the value of your investment could be reduced.

 There
is no assurance that we will be able to obtain additional funding if it is needed, or that such funding, if available, will be obtainable
on terms and conditions favorable to or affordable by us. If we cannot obtain needed funds, we may be forced to curtail our activities.

 Risks
Relating to our Management

 The
loss of the services of any of our officers or our failure to timely identify and retain competent personnel could negatively impact
our ability to develop our products and sales.

 The
development of our business will continue to place a significant strain on our limited personnel, management, and other resources. Our
future success depends upon the continued services of our executive officers, Xu Huibo, our President and Chairman of the Board of Director,
Zhou Hongxiao, Chief Executive Officer (CEO), Secretary and director, and our Chief Financial Officer, Kang Liping. They are developing
our business, which will depend on our ability to identify and retain competent employees with the skills required to execute our business
objectives. The loss of the services of any of our officers or our failure to timely identify and retain competent personnel could negatively
impact our ability to develop our products and services, which could adversely affect our financial results and impair our growth.

 If
we are unable to hire, retain or motivate qualified personnel, consultants, independent contractors, and advisors, we may not be able
to grow effectively.

 Our
performance will be largely dependent on the talents and efforts of highly skilled individuals. Future success depends on our continuing
ability to identify, hire, develop, motivate and retain highly qualified personnel for all areas of our organization. Competition for
such qualified employees is intense. If we do not succeed in attracting excellent personnel or in retaining or motivating them, we may
be unable to grow effectively. In addition, all future success depends largely on our ability to retain key consultants and advisors.
We cannot assure that any skilled individual will agree to become an employee, consultant, or independent contractor of Longduoduo Company
Limited. Our inability to retain their services could negatively impact our business and our ability to execute our business strategy.

 Our
internal controls over financial reporting may not be effective and our independent registered public accounting firm may not be able
to certify as to their effectiveness, which could have a significant and adverse effect on our business and reputation.

 As
a new public reporting company, we will be in a continuing process of developing, establishing, and maintaining internal controls and
procedures that will allow our management to report on, and our independent registered public accounting firm to attest to, our internal
controls over financial reporting if and when required to do so under Section 404 of the Sarbanes-Oxley Act of 2002. Although our independent
registered public accounting firm is not required to attest to the effectiveness of our internal control over financial reporting pursuant
to Section 404(b) of the Sarbanes-Oxley Act until the date we are no longer an emerging growth company, our management will be required
to report on our internal controls over financial reporting under Section 404. If we fail to achieve and maintain the adequacy of our
internal controls, we would not be able to conclude on an ongoing basis that we have effective internal controls over financial reporting
in accordance with Section 404. At such time, our independent registered public accounting firm may issue a report that is adverse in
the event it is not satisfied with the level at which our controls are documented, designed or operating. Moreover, our testing, or the
subsequent testing by our independent registered public accounting firm that must be performed may reveal other material weaknesses or
that the material weaknesses have not been fully remediated. If we do not remediate our material weaknesses, or if other material weaknesses
are identified or we are not able to comply with the requirements of Section 404 in a timely manner, our reported financial results could
be materially misstated or could subsequently require restatement, we could receive an adverse opinion regarding our internal controls
over financial reporting from our independent registered public accounting firm and we could be subject to investigations or sanctions
by regulatory authorities, which would require additional financial and management resources, and the market price of our stock could
decline.

 Limitations
on director and officer liability and indemnification of our Company's officers and directors by us may discourage shareholders
from bringing a lawsuit against an officer or director.

 Our
Company's certificate of incorporation and bylaws provide, with certain exceptions as required by governing state law, that a director
or officer shall not be personally liable to us or our shareholders for breach of fiduciary duty as a director or officer, except for
acts or omissions which involve intentional misconduct, fraud or knowing violation of law, or unlawful payments of dividends. These provisions
may discourage shareholders from bringing a lawsuit against a director or officer for breach of fiduciary duty and may reduce the likelihood
of derivative litigation brought by shareholders on the Company's behalf against a director or officer.

 Our
management has limited experience managing a public company.

 At
the present time, our management has limited experience in managing a public company. This may hinder our ability to establish effective
controls and systems and comply with all applicable requirements associated with being a public company. If compliance problems result,
these problems could have a material adverse effect on our business, financial condition or results of operations. As a public company,
we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley
Act of 2002, or Sarbanes-Oxley Act, and the Dodd-Frank Act of 2010, as well as rules subsequently implemented by the SEC, have imposed
various requirements on public companies, including requiring changes in corporate governance practices. Our management and other personnel
will need to devote a substantial amount of time to our new compliance requirements. Moreover, these requirements will increase our legal,
accounting and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect it will
be difficult and expensive for us to obtain director and officer liability insurance. These requirements could also make it more difficult
for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.

 We
may have difficulty establishing adequate management, legal and financial controls in the PRC.

 We
may have difficulty in hiring and retaining a sufficient number of qualified employees to serve as our management staff. As a result
of these factors, we may experience difficulty in establishing management, legal and financial controls, collecting financial data and
preparing financial statements, books of account and corporate records and instituting business practices that meet western standards.
Therefore, we may, in turn, experience difficulties in implementing and maintaining adequate internal controls as will be required under
Section 404 of the Sarbanes Oxley Act of 2002.

 Risks
Related to Doing Business in the PRC

in United States and China relations, as well as relations with other countries, and/or regulations may adversely impact our business,
our operating results, our ability to raise capital and the market price of our shares.

 The
U.S. government, including the SEC, has made statements and taken certain actions that led to changes to United States and international
relations, and will impact companies with connections to the United States or China, including imposing several rounds of tariffs affecting
certain products manufactured in China, imposing certain sanctions and restrictions in relation to China and issuing statements indicating
enhanced review of companies with significant China-based operations. It is unknown whether and to what extent new legislation, executive
orders, tariffs, laws or regulations will be adopted, or the effect that any such actions would have on companies with significant connections
to the U.S. or to China, our industry or on us. Any unfavorable government policies on cross-border relations and/or international trade,
including increased scrutiny on companies with significant China-based operations, capital controls or tariffs, may affect our ability
to raise capital and the market price of our shares.

 Furthermore,
the SEC has issued statements primarily focused on companies with significant China-based operations, such as us. For example, on July
30, 2021, Gary Gensler, Chairman of the SEC, issued a Statement on Investor Protection Related to Recent Developments in China, pursuant
to which Chairman Gensler stated that he has asked the SEC staff to engage in targeted additional reviews of filings for companies with
significant China-based operations. The statement also addressed risks inherent in companies with a Variable Interest Entity, or a VIE
structure. We do not have a VIE structure and are not in an industry that is subject to foreign ownership limitations by China. Further,
we believe that we have robust disclosures relating to our operations in China, including the relevant risks noted in Chairman Gensler's
statement. However, it is possible that the Company's periodic reports and other filings with the SEC may be subject to enhanced
review by the SEC and this additional scrutiny could affect our ability to effectively raise capital in the United States.

 In
response to the SEC's July 30 statement, the China Securities Regulatory Commission (CSRC) announced on August 1, 2021, that "it
is our belief that Chinese and U.S. regulators shall continue to enhance communication with the principle of mutual respect and cooperation,
and properly address the issues related to the supervision of China-based companies listed in the U.S. so as to form stable policy expectations
and create benign rules framework for the market." While the CSRC will continue to collaborate "closely with different stakeholders
including investors, companies, and relevant authorities to further promote transparency and certainty of policies and implementing measures,"
it emphasized that it "has always been open to companies' choices to list their securities on international or domestic markets
in compliance with relevant laws and regulations."

 If
any new legislation, executive orders, tariffs, laws and/or regulations are implemented, if existing trade agreements are renegotiated
or if the U.S. or Chinese governments take retaliatory actions due to the recent U.S.-China tension, such changes could have an adverse
effect on our business, financial condition and results of operations, our ability to raise capital and the market price of our shares.

 The
operations of our subsidiaries in China, as well as our financial operations in the U.S. to the extent that they affect our subsidiaries
in China, will be subject to a high level of control by the national and provincial bureaucracies in the PRC. Exercise by government
authorities of that control could significantly interfere with our ability to conduct our operations in the best interests of our company
and its shareholders, which could cause the value of our common stock to decline and limit or prevent our efforts to finance the operations
of our Chinese subsidiaries.

 The
government of the PRC is highly bureaucratized, as are the provincial governments in China. Whereas the authority of agencies in the
U.S. government is restricted to a stated mandate by principles and regulations of administrative law, agencies of the PRC government
have broad authority to impose and administer regulations, and to collect information, as they deem in the best interests of the nation.
As a result, our Company's Board of Directors may find its ability to develop and implement a business plan constrained by the
regulatory activities of government agencies in the PRC, which are able to exert substantial and wide-ranging control over our Company's
operations, both those of our Chinese subsidiaries, and the financial operations of Longduoduo.

 The
PRC agencies that will exercise significant control over our Company's operations include:

 China
Securities Regulatory Commission ("CSRC"), which since March 2023 has imposed extensive reporting requirements and other
regulations on companies structured as ours: offshore holding companies with operations based in China. The CSRC now requires that such
companies obtain pre-approval of offshore securities listings and offshore securities offerings, and the CSRC, in reviewing such filings,
has broad discretion to limit or prevent offshore financing activities that CSRC believes put the interests of China at risk, including
risks attendant to indirect offshore investment in companies that control significant data, personal or otherwise, and companies involved
in a wide range of industries that CSRC deems essential to the PRC.

 State
Administration of Foreign Exchange ("SAFE"), which governs inflows and outflows of capital with respect to the PRC, and has
broad authority to regulate or restrict, by registration requirements or prohibitions, cross-border transactions and currency exchange
as needed to protect the interests of the PRC.

 Cyberspace
Administration of China ("CAC"), which has broad authority to regulate conduct within the PRC and offshore as it relates
to cyberspace activities touching on the PRC. Among the proposed regulations under review by the CAC are a requirement that China-based
enterprises holding significant user data be required to undergo review and approval by CAC before soliciting offshore investment.

 Ministry
of Commerce ("MOFCOM"), which has broad regulatory authority over commercial activity in the PRC, with particular focus on
foreign-invested commercial activity. Among MOFCOM's activities is reviewing offshore investments in Chinese enterprises to assure
the capital is used for purposes that fall within the pre-approved business plan of the Chinese recipient.

 Investors
considering investment in Longduoduo, therefore, should understand that the control of our Board of Directors over the plans and operations
of our Company will be subject to the extensive control that the government of China may exercise over both our Chinese subsidiaries
and the activities of its U.S. parent company as they involve our Chinese subsidiaries. Our Board may find, at times, that actions it
considers in the best interests of our Company and its shareholders are restricted or prevented by policies of one or more Chinese government
agencies. These restrictions, in turn, may make our public securities less valuable and interfere with our efforts to raise capital for
the operations of our Chinese subsidiaries.

 The
government of China will make a direct intervention into the operations of a China-based company and take control of its operations or
significantly restrict its operations if the government believes such action is in the best interests of the Chinese nation.

 The
Chinese government may intervene or influence our operations at any time, or may exert control over operations of our business, which
could result in a material change in our operations and/or the value of our securities. Any actions by the Chinese government to exert
more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers could significantly
limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to
significantly decline or be worthless. The government of the PRC is not bound by principles of substantive due process similar to those
binding on the U.S. government. Therefore, the government of the PRC considers itself charged with unrestricted responsibility for the
well-being of its nation, and will intervene in the economy of the PRC in general or in the affairs of an individual enterprise within
the PRC, as it deems appropriate to protect the well-being of the PRC. Such intervention can take the form of restrictions on the operations
of the enterprise, denial of approvals required under Chinese law to conduct the business of the enterprise, influence exerted on the
appointment of management, and has in some cases involved government seizure of the assets of an enterprise. A U.S. investor in Longduoduo
will be at risk of an intervention by the PRC government in the Chinese medical services business in general or the business of our Chinese
subsidiaries in particular, as well as the risk that the PRC government will impose new restrictions on the ability of Longduoduo to
fund the operations of our Chinese subsidiaries, such as restrictions on the use of offshore sources to fund the operations of our Chinese
subsidiaries. Any such intervention by the PRC government in the operations of our Chinese subsidiaries could undermine our business
plan and cause the value of an investment in Longduoduo to significantly decline or become worthless.

 Failure to comply
with any PRC laws and regulations may adversely affect our business, investments and results of operations.

 Our
China operations are subject to PRC laws and regulations including but not limited to the laws and regulations
on taxation, employment and social welfare, product quality and consumer protection, foreign investment, foreign exchange, online trading
and E-commerce, food business and so on. Compliance with, and monitoring of, applicable laws and regulations may
be difficult, time consuming and costly. A failure to comply with applicable laws or regulations, as interpreted and applied,
could have a material adverse effect on our business and results of operations.

in the policies of the PRC government could have an adverse effect on our business.

 Policies
of the PRC government can have significant effects on the economic conditions in the PRC. Although the PRC government has been pursuing
economic reform policies and transitioning to a market-oriented economy, there is no assurance that the government will continue to pursue
such policies or that such policies may not be significantly altered, especially in the event of a change in leadership, social or political
disruption, or other circumstances affecting the PRC's political, economic and social conditions. Further, regulatory agencies
in China may periodically, and sometimes abruptly with little to no advance notice, change their enforcement practices. Therefore, prior
enforcement activity, or lack of enforcement activity, is not necessarily predictive of future actions. Our business could be adversely
affected by changes in PRC government policies, including but not limited to changes in policies relating to taxation, currency conversion,
imports and exports, and ownership of private enterprises.

 Uncertainties
with respect to the PRC legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in
laws and regulations in China could adversely affect us and limit the legal protections available to you and us.

 Our
operating subsidiaries are incorporated under and governed by the laws of the PRC. The PRC legal system is based on written statutes.
Prior court decisions may be cited for reference but have limited precedential value. In 1979, the PRC government began to promulgate
a comprehensive system of laws and regulations governing economic matters in general, such as foreign investment, corporate organization
and governance, commerce, taxation and trade. As a significant part of our business is conducted in China, our operations are principally
governed by PRC laws and regulations. However, since the PRC legal system continues to evolve rapidly, the interpretations of many laws,
regulations and rules are not always uniform and enforcement of these laws, regulations and rules involves uncertainties, which may limit
legal protections available to us. Uncertainties due to evolving laws and regulations could also impede the ability of a China-based
company, such as our company, to obtain or maintain permits or licenses required to conduct business in China. In the absence of required
permits or licenses, governmental authorities could impose material sanctions or penalties on us. In addition, some regulatory requirements
issued by certain PRC government authorities may not be consistently applied by other PRC government authorities (including local government
authorities), thus making strict compliance with all regulatory requirements impractical, or in some circumstances impossible. For example,
our PRC subsidiary may have to resort to administrative and court proceedings to enforce the legal protection that we enjoy either by
law or contract. However, since PRC administrative and court authorities have discretion in interpreting and implementing statutory and
contractual terms, it may be more difficult to predict the outcome of administrative and court proceedings and the level of legal protection
we enjoy than in more developed legal systems. Furthermore, the PRC legal system is based in part on government policies and internal
rules, some of which are not published on a timely basis or at all and may have retroactive effect. As a result, we may not be aware
of our violation of these policies and rules until sometime after the violation. Such uncertainties, including uncertainty over the scope
and effect of our contractual, property (including intellectual property) and procedural rights, could materially and adversely affect
our business and impede our ability to continue our operations.

 Intellectual
property rights and confidentiality protections in China may also not be as effective as in the United States or other countries. In
addition, we cannot predict the effects of future developments in the PRC legal system on our business operations, including the promulgation
of new laws, or changes to existing laws or the interpretation or enforcement thereof. These uncertainties could limit the legal protections
available to us and our investors, including you. Moreover, any litigation in China may be protracted and result in substantial costs
and diversion of our resources and management attention.

 The
PRC government has significant oversight and discretion over the conduct of our business and may intervene or influence our operations
as the government deems appropriate to further regulatory, political and societal goals. The PRC government has recently published new
policies that significantly affected certain industries such as the education and internet industries, and we cannot rule out the
possibility that it will in the future release regulations or policies regarding our industry that could adversely affect our business,
financial condition and results of operations. Furthermore, the PRC government has recently indicated an intent to exert more oversight
and control over securities offerings and other capital markets activities that are conducted overseas and foreign investment in China-based
companies. Any such intervention in or influence on our business operations or action to exert more oversight and control over securities
offerings and other capital markets activities, once taken by the PRC government, could adversely affect the business, financial condition
and results of operations and the value of China-based companies, or significantly limit or completely hinder our ability to offer or
continue to offer securities to investors and cause the value of such securities to significantly decline or in extreme cases, become
worthless.

 PRC
regulation of loans to, and direct investments in, PRC entities by offshore holding companies may delay or prevent us from using our
capital reserves to make loans or additional capital contributions to our PRC operating subsidiaries.

 As
an offshore holding company with PRC subsidiaries, we may transfer funds to our PRC subsidiaries or finance our operating entity by means
of loans or capital contributions. Any capital contributions or loans that we, as an offshore entity, make to our Company's PRC
subsidiaries, are subject to PRC regulations. Any loans to our PRC subsidiaries, which are foreign-invested enterprises, cannot exceed
statutory limits based on the difference between the amount of our investments and registered capital in such subsidiaries, and shall
be registered with SAFE, or its local counterparts. Furthermore, any capital increase contributions we make to our PRC subsidiaries,
which are foreign-invested enterprises, are subject to the requirement of making necessary filings in FICMIS, and registration with other
government authorities in China. We may not be able to obtain these government registrations or approvals on a timely basis, if at all.
If we fail to obtain such approvals or make such registration, our ability to make equity contributions or provide loans to our Company's
PRC subsidiaries or to fund their operations may be negatively affected, which may adversely affect their liquidity and ability to fund
their working capital and expansion projects and meet their obligations and commitments. As a result, our liquidity and our ability to
fund and expand our business may be negatively affected.

 Because
our principal assets are located outside of the United States and because all of our directors and all our officers reside in China,
it may be difficult for you to use the United States Federal securities laws to enforce your rights against us and our officers or to
enforce judgments of United States courts against us or them in the PRC.

 Our
Company conducts substantially all of its operations in China, and substantially all of the assets reflected on our balance sheet are
located in China. In addition, all members of our board of directors and all of our senior executive officers reside within China and
are PRC nationals. As a result, it may be difficult for our shareholders to effect service of process upon those persons inside China.
In addition, China does not have treaties providing for the reciprocal recognition and enforcement of judgments of courts with the United
States. Therefore, recognition and enforcement in China of judgments of a court in the United States in relation to any matter not subject
to a binding arbitration provision may be difficult or impossible.

 Shareholder
claims that are common in the United States, including securities law class actions and fraud claims, generally are difficult to pursue
as a matter of law or practicality in China. For example, in China, there are significant legal and other obstacles to obtaining information
needed for shareholder investigations or litigation outside China or otherwise with respect to foreign entities. Although the local authorities
in China may establish a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to
implement cross-border supervision and administration, such regulatory cooperation with the securities regulatory authorities in the
Unities States have not been efficient in the absence of a mutual and practical cooperation mechanism.

 The
recent joint statement by the SEC and PCAOB and the Holding Foreign Companies Accountable Act calls for additional and more stringent
criteria to be applied to emerging market companies upon assessing the qualification of their auditors, especially the non-U.S. auditors
who are not inspected by the PCAOB. Furthermore, in 2023, the U.S. Congress passed, and the President signed, the Accelerating Holding
Foreign Companies Accountable Act, which amended the HFCA Act and requires the SEC to prohibit an issuer's securities from trading
on any U.S. stock exchanges if its auditor is not subject to PCAOB inspections for two consecutive years (instead of three mandated in
the HFCAA). These developments could add uncertainties to our business operations.

 Pursuant
to the Holding Foreign Companies Accountable Act ("HFCAA"), as adopted by the United States Congress in 2020, the Public
Company Accounting Oversight Board (the "PCAOB") issued a Determination Report on December 16, 2021 which found that the
PCAOB was unable to inspect or investigate completely registered public accounting firms headquartered in the PRC because of a position
taken by one or more authorities in mainland China. Under the HFCAA (as amended by the Consolidated Appropriations Act – 2023),
an issuer's securities may be prohibited from trading on a U.S. stock exchange or facility if its auditor is not inspected by the
PCAOB for two consecutive years (reduced by Congress in 2023 from three consecutive years in the original HFCAA).

 On
August 26, 2022, the China Securities Regulatory Commission ("CSRC"), the Ministry of Finance of China, and the PCAOB signed
a protocol governing inspections and investigations of audit firms based in China and Hong Kong. On December 15, 2022, the PCAOB
issued a new Determination Report which: (1) vacated the December 16, 2021 Determination Report; and (2) concluded that the PCAOB had
been able to conduct inspections and investigations completely in the PRC in 2022. The December 15, 2022 Determination Report cautions,
however, that authorities in the PRC might take positions at any time that would prevent the PCAOB from continuing to inspect or investigate
completely. As required by the HFCAA, if in the future the PCAOB determines it no longer can inspect or investigate completely because
of a position taken by an authority in the PRC, the PCAOB will act expeditiously to consider whether it should issue a new determination.
If the PCAOB is not able to fully conduct inspections of our auditor's work papers in the PRC, our securities may be prohibited
from trading on a U.S. stock exchange or facility if our auditor is not inspected by the PCAOB for two consecutive years, and this ultimately
could result in our common stock being barred from listing in the United States, which would likely prevent our shareholders from being
able to sell their shares until the bar was lifted.

recently engaged Bush & Associates CPA LLC as its independent auditor. Bush & Associates is headquartered in the State of Nevada.
The PCAOB is able to, and does, fully conduct inspections of our auditor's work papers. There remains a risk, however, that the
government of the PRC might in the future impose restrictions on the communication of information to auditors or by auditors of issuers
whose operations are located within the PRC, in such a way that investors in the securities of such issuers do not receive the full benefit
of the audits. In that situation, it could occur that the SEC would bar trading platforms subject to U.S. jurisdiction from listing Longduoduo's
securities for trading. Such an occurrence would be likely to cause the value of Longduoduo's securities to diminish significantly.

 However,
the recent developments would add uncertainties to our situation and we cannot assure you whether regulatory authorities would apply
additional and more stringent criteria to us after considering the effectiveness of our auditor's audit procedures and quality
control procedures, adequacy of personnel and training, or sufficiency of resources, geographic reach or experience as it relates to
the audit of our financial statements. It remains unclear what the SEC's implementation process related to the June 2021 interim
final amendments will entail or what further actions the SEC or the PCAOB will take to address these issues and what impact those actions
will have on U.S. companies that have significant operations in the PRC and have securities listed on a U.S. stock exchange (including
a national securities exchange or over-the-counter stock market). In addition, the June 2021 interim final amendments and any additional
actions, proceedings, or new rules resulting from these efforts to increase U.S. regulatory access to audit information could create
some uncertainty for investors, the market price of our common stock could be adversely affected, and we could be delisted if we and
our auditor are unable to meet the PCAOB inspection requirement or being required to engage a new audit firm, which would require significant
expense and management time.

 Restrictions
contained in Chinese law on the ability of overseas securities regulators to collect information in China may deny investors in our Company
the benefits of U.S. securities regulation.

 China
has often restricted U.S. regulators' access to information and limited regulators' ability to investigate or pursue remedies
with respect to China-based issuers, generally citing to state secrecy and national security laws, blocking statutes, or other laws or
regulations. In addition, according to Article 177 of the PRC Securities Law, which became effective in March 2020, no overseas securities
regulator can directly conduct investigations or evidence collection activities within the PRC and no entity or individual in China may
provide documents and information relating to securities business activities to overseas regulators without Chinese government approval.
The SEC, U.S. Department of Justice, and other U.S. authorities face substantial challenges in bringing and enforcing actions against
China-based issuers and their officers and directors. As a result, investors in our Company may not benefit from a regulatory environment
that fosters effective enforcement of U.S. federal securities laws.

 According
to Article 177, there are uncertainties as to the procedures and requisite timing for the U.S. securities regulatory agencies
to conduct investigations and collect evidence within the territory of the PRC. If the U.S. securities regulatory
agencies are unable to conduct such investigations, there exists a risk that they may determine to suspend or de-register our registration
with the SEC and may also delist our securities from OTC Markets or other applicable trading market within the US.

 Governmental
control of currency conversion may affect the value of your investment.

 The
People's Republic of China (PRC) government imposes controls on the convertibility of Renminbi (RMB) into foreign currencies and,
in certain cases, the remittance of currency out of the PRC. We receive substantially all of our revenues in RMB, which is currently
not a freely convertible currency. Shortages in the availability of foreign currency may restrict our ability to remit sufficient foreign
currency to pay dividends, or otherwise satisfy foreign currency dominated obligations. Under existing PRC foreign exchange regulations,
payments of current account items, including profit distributions, interest payments and expenditures in connection with a commercial
transaction, can be made in foreign currencies without prior approval from the PRC State Administration of Foreign Exchange by complying
with certain procedural requirements. However, approval from appropriate governmental authorities is required where RMB is to be converted
into foreign currency and remitted out of PRC to pay capital expenses such as the repayment of bank loans denominated in foreign currencies.

 The
PRC government also may at its discretion restrict access in the future to foreign currencies for current account transactions. If the
foreign exchange control system prevents us from obtaining sufficient foreign currency to satisfy our currency demands, we may not be
able to pay certain of our expenses as they come due, finance our cash requirements, service debt or make dividend or other distributions
to our shareholders, all of which may adversely affect your investment.

 The
fluctuation of RMB may materially and adversely affect your investment.

 The
value of the RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in the PRC's
political and economic conditions. As we rely entirely on revenues earned in the PRC, any significant revaluation of RMB may materially
and adversely affect our cash flows, revenues and financial condition. For example, to the extent that we need to convert U.S. dollars
we receive from an offering of our securities into RMB for our operations, appreciation of the RMB against the U.S. dollar could have
a material adverse effect on our business, financial condition and results of operations. Conversely, if we decide to convert our RMB
into U.S. dollars for the purpose of making dividend payments on our common stock or for other business purposes and the U.S. dollar
appreciates against the RMB, the U.S. dollar equivalent of the RMB we convert would be reduced. In addition, the depreciation of significant
U.S. dollar denominated assets could result in a charge to our income statement and a reduction in the value of these assets.

 We
may become subject to a variety of laws and regulations in the PRC regarding privacy, data security, cybersecurity, and data protection.
We may be liable for improper use or appropriation of personal information provided by our customers.

 We
may become subject to a variety of laws and regulations in the PRC regarding privacy, data security, cybersecurity, and data protection.
These laws and regulations are continuously evolving and developing. The scope and interpretation of the laws that are or may be applicable
to us are often uncertain and may be conflicting, particularly with respect to foreign laws. In particular, there are numerous laws and
regulations regarding privacy and the collection, sharing, use, processing, disclosure, and protection of personal information and other
user data. Such laws and regulations often vary in scope, may be subject to differing interpretations, and may be inconsistent among
different jurisdictions.

 We
expect to obtain information about various aspects of our operations as well as regarding our employees and third parties. We also maintain
information about various aspects of our operations as well as regarding our employees. The integrity and protection of our customer,
employee and company data is critical to our business. Our customers and employees expect that we will adequately protect their personal
information. We are required by applicable laws to keep strictly confidential the personal information that we collect, and to take adequate
security measures to safeguard such information.

 The
PRC Criminal Law, as amended by its Amendment 7 (effective on February 28, 2009) and Amendment 9 (effective on November 1, 2015), prohibits
institutions, companies and their employees from selling or otherwise illegally disclosing a citizen's personal information obtained
during the course of performing duties or providing services or obtaining such information through theft or other illegal ways.

 On
November 7, 2016, the Standing Committee of the PRC National People's Congress issued the Cyber Security Law of the PRC, or Cyber
Security Law, which became effective on June 1, 2017. Pursuant to the Cyber Security Law, network operators must not, without users'
consent, collect their personal information, and may only collect users' personal information necessary to provide their services.
Providers are also obliged to provide security maintenance for their products and services and shall comply with provisions regarding
the protection of personal information as stipulated under the relevant laws and regulations. We believe that we are in compliance with
the Cyber Security Law, given that: (i) our products and services are sold offline; and (ii) we do not have an online platform.

 The
Civil Code of the PRC (issued by the PRC National People's Congress on May 28, 2020 and effective from January 1, 2021) provides
the main legal basis for privacy and personal information infringement claims under the Chinese civil laws. PRC regulators, including
the Cyberspace Administration of China, MIIT, and the Ministry of Public Security have been increasingly focused on regulation in the
areas of data security and data protection.

 The
PRC regulatory requirements regarding cybersecurity are constantly evolving. For instance, various regulatory bodies in China, including
the Cyberspace Administration of China, the Ministry of Public Security and the SAMR, have enforced data privacy and protection laws
and regulations with varying and evolving standards and interpretations. In April 2020, the Chinese government promulgated Cybersecurity
Review Measures, which came into effect on June 1, 2020. According to the Cybersecurity Review Measures, operators of critical information
infrastructure must pass a cybersecurity review when purchasing network products and services which do or may affect national security.

 In
November 2016, the Standing Committee of China's National People's Congress passed China's first Cybersecurity Law
("CSL"), which became effective in June 2017. The CSL is the first PRC law that systematically lays out the regulatory requirements
on cybersecurity and data protection, subjecting many previously under-regulated or unregulated activities in cyberspace to government
scrutiny. The legal consequences of violation of the CSL include penalties of warning, confiscation of illegal income, suspension of
related business, winding up for rectification, shutting down the websites, and revocation of business license or relevant permits. In
April 2020, the Cyberspace Administration of China and certain other PRC regulatory authorities promulgated the Cybersecurity Review
Measures, which became effective in June 2020. Pursuant to the Cybersecurity Review Measures, operators of critical information infrastructure
must pass a cybersecurity review when purchasing network products and services which do or may affect national security. On July 10,
2021, the Cyberspace Administration of China issued a revised draft of the Measures for Cybersecurity Review for public comments ("Draft
Measures"), which required that, in addition to "operator of critical information infrastructure," any "data
processor" carrying out data processing activities that affect or may affect national security should also be subject to cybersecurity
review, and further elaborated the factors to be considered when assessing the national security risks of the relevant activities, including,
among others, (i) the risk of core data, important data or a large amount of personal information being stolen, leaked, destroyed, and
illegally used or exited the country; and (ii) the risk of critical information infrastructure, core data, important data or a large
amount of personal information being affected, controlled, or maliciously used by foreign governments after listing abroad. The Cyberspace
Administration of China has said that under the proposed rules companies holding data on more than 1,000,000 users must now apply for
cybersecurity approval when seeking listings in other nations because of the risk that such data and personal information could be "affected,
controlled, and maliciously exploited by foreign governments," The cybersecurity review will also investigate the potential national
security risks from overseas IPOs. We do not know what regulations will be adopted or how such regulations will affect us and the quotation
of our securities on the OTC Pink Market. In the event that the Cyberspace Administration of China determines that we are subject to
these regulations, quotation of our securities on the OTC may be prohibited and we may be subject to fines and penalties. We believe
that we will not be subject to the cybersecurity review by the CAC, given that: (i) we are not an "operator of critical information
infrastructure" or a "data processor" carrying out data processing activities that affect or may affect national security;
(ii) we do not possess a large amount of personal information in our business operations; and (iii) data processed in our business does
not have a bearing on national security and thus may not be classified as core or important data by the authorities. However, there remains
uncertainty as to how the 2021 Measures will be interpreted or implemented and whether the PRC regulatory agencies, including the CAC,
may adopt new laws, regulations, rules, or detailed implementation and interpretation related to the 2021 Measures. If any such new laws,
regulations, rules, or implementation and interpretation comes into effect, we will take all reasonable measures and actions to comply
and to minimize the adverse effect of such laws on us.

 We
cannot assure you that PRC regulatory agencies, including the CAC, would take the same view as we do, and there is no assurance that
we can fully or timely comply with such laws. In the event that we are subject to any mandatory cybersecurity review and other specific
actions required by PRC regulatory agencies, we face uncertainty as to whether any clearance or other required actions can be timely
completed, or at all. Given such uncertainty, we may be further required to suspend our relevant business, shut down our website, or
face other penalties, which could materially and adversely affect our business, financial condition, and results of operations.

 The
Chinese government can take regulatory actions and statements to regulate business operations in China with little to no advance notice
at any time, including cracking down on illegal activities in the securities market, enhancing supervision over China-based companies
listed overseas using variable interest entity structure, adopting new measures to extend the scope of cybersecurity reviews, and expanding
the efforts in anti-monopoly enforcement. Rules and regulations and the enforcement or interpretation thereof in China can also change
with little to no advance notice, and actions related to oversight and control over offerings that are conducted overseas in our China
based entities could cause the value of Longduoduo's securities to significantly decline or be worthless.

 The
Chinese government has taken and continues to take regulatory actions and statements to regulate over virtually every sector of the Chinese
economy through regulation and state ownership, sometimes with very little advance notice. Our ability to operate through our subsidiaries
in China may be harmed by changes in its laws and regulations, including those relating to taxation, environmental regulations, land
use rights, cybersecurity, property and other matters. The central or local governments of these jurisdictions may impose new, stricter
regulations or interpretations of existing regulations that would require additional expenditures and efforts on our part to ensure our
compliance with such regulations or interpretations. Accordingly, government actions in the future, including any decision not to continue
to support recent economic reforms and to return to a more centrally planned economy or regional or local variations in the implementation
of economic policies, could result in a material change in our operations in China and could limit or completely hinder our ability to
offer or continue to offer securities to investors or require us to divest ourselves of any interest we then hold in China properties
or joint ventures. Any such actions (including divesture or similar actions) could result in a material adverse effect on us and on your
investment in us and could render our securities and your investment in our securities worthless.

 As
such, the Company's business segments and entities may be subject to various government and regulatory interference in the provinces
in which they operate. The Company could be subject to new regulation by various political and regulatory entities, including various
local and municipal agencies and government sub-divisions. The Company may incur increased costs necessary to comply with existing and
newly adopted laws and regulations or penalties for any failure to comply. As a result, the fast-changing rules and regulation could
potentially impact our operation and profitability in China and as a result, cause the value of Longduoduo's securities to significantly
decline or even become worthless.

 We
will require the approval of the CSRS before our common stock may become listed on the OTCQB, Nasdaq or any U.S. securities exchange.
If we are unable to obtain CSRC's approval, our ability to raise capital will be limited, which would likely limit the growth of
our company.

 We
intend to fund the growth of our business in large part by raising capital in Longduoduo through its sale of securities outside of the
PRC. The capital markets in the U.S. that we might access for financing will depend in large part on our ability to secure a listing
on Nasdaq, OTCQX or one of the registered securities exchanges. The Trial Administrative Measures adopted on March 31, 2023 require that
at the time we apply to an exchange (which for this purpose will include Nasdaq, OTCQB or OTCQX), we must file an extensive application
with the CSRC and await approval by CSRC of the listing. The CSRC has indicated an intent to use these applications in order to protect
the PRC from foreign control of (or significant influence over) important Chinese businesses. We cannot determine what criteria the CSRC
will apply for this purpose. The regulations, therefore, create for our investors a risk that our efforts to finance our Chinese subsidiaries
by selling Longduoduo securities abroad will be restricted, delayed or eliminated by CSRC's implementation of the listing requirements
in the Trial Administrative Measures. That risk, if realized, could prevent us from expanding our Chinese subsidiaries's business,
which could reduce or eliminate the value of Longduoduo common stock.

 If
Longduoduo common stock becomes listed on the OTCQB or an exchange, we will be required to obtain the approval of the PRC government
for a business combination, the issuance of our common stock, or maintaining our status as a publicly listed company outside China.

 On
February 17, 2023, the CSRC promulgated the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies
(the "Trial Administrative Measures"), which took effect on March 31, 2023. On the same date, the CSRC published on CSRC's
official website Supporting Guidance Rules No. 1 through No. 5, Notes on the Trial Administrative Measures, Notice on Administration
Arrangements for the Filing of Overseas Listings by Domestic Enterprises and relevant CSRC Answers to Reporter Questions or, collectively,
the "Guidance Rules and Notice." The Trial Administrative Measures, together with the Guidance Rules and Notice, mandate
that issuers whose principal business activities occur in the PRC must, within three business days after filing with the offshore regulator
an application for an offshore offering or listing of securities on an exchange, submit to CSRC an application for review. The Trial
Administrative Measures apply to overseas securities offerings and/or listings conducted by companies incorporated in the PRC, PRC domestic
companies, and companies incorporated overseas with operations primarily in the PRC, indirect offerings. The Trial Administrative Measures
require (1) the filing of the overseas offering and listing plan by the PRC domestic companies with the CSRC under certain conditions,
(2) the filing by the underwriter with the CSRC under certain conditions and (3) the submission of an annual report to the CSRC within
the required timeline. The Trial Administrative Measures include: (1) criteria to determine whether an issuer will be required to go
through the filing procedures under the Trial Administrative Measures; (2) exemptions from immediate filing requirements for issuers
that have already been listed in foreign securities markets, including U.S. markets, prior to the effective date of the Trial Administrative
Measures; (3) a negative list of types of issuers banned from listing or offering overseas, such as issuers whose affiliates have been
recently convicted of bribery and corruption; (4) issuers' compliance with web security, data security, and other national security
laws and regulations; (5) issuers' filing and reporting obligations, such as obligation to file with the CSRC after it submits
an application for initial public offering to overseas regulators, and obligation after offering or listing overseas to file with the
CSRC after it completes subsequent offerings and to report to the CSRC material events including change of control or voluntary or forced
delisting of the issuer; and (6) the CSRC's authority to fine both issuers and their relevant shareholders for failure to comply
with the Trial Administrative Measures, including failure to comply with filing obligations or committing fraud and misrepresentation.
Fines of up to 10 million RMB (approximately US$1.4 million) for non-compliance are authorized.

plans to apply for listing on the OTCQB or Nasdaq as soon as we are eligible; if accepted, we would then be subject to the requirements
of the Trial Administrative Measures with respect to any future securities offerings made outside of China. As the Trial Administrative
Measures are newly issued, there remain uncertainties regarding its interpretation and implementation. Therefore, we cannot assure you
that we will be able to complete the filings for our future offerings and fully comply with the relevant new rules on a timely basis,
if at all. In addition, we face uncertainty regarding the criteria that CSRS will apply when reviewing filings for approval, and cannot
assure that the process will not cause a substantial reduction in our ability to raise capital in the U.S.

 Risks
Relating to Our Common Stock

 We
are an emerging growth company and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies,
our common stock may be less attractive to investors.

 We
are an emerging growth company, as defined in the JOBS Act, and we are eligible to take advantage of certain exemptions from various
reporting requirements applicable to other public companies. We will remain an emerging growth company until the earliest to occur of:
(i) the last day of the fiscal year in which we have at least $1.07 billion in annual revenue; (ii) the last day of the fiscal year in
which we are deemed to be a "large accelerated filer," as defined in Rule 12b-2 under the Exchange Act, which would occur
if the market value of our Common Stock held by non-affiliates exceeded $700 million as of the last business day of the second fiscal
quarter of such year; (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt securities during the prior
three-year period; and (iv) the last day of the fiscal year ending after the fifth anniversary of our initial public offering. The exemptions
available to emerging growth companies include the right to present only two years of audited financial statements in our registration
statements and annual reports, an exemption from the auditor attestation requirement of Section 404 of the Sarbanes-Oxley Act relating
to internal controls, reduced disclosure about executive compensation arrangements, and no requirement to seek non-binding advisory votes
on executive compensation or golden parachute arrangements. Some of these exemptions are also available to us as a smaller reporting
company (i.e. a company with less than $250 million of its voting equity held by non-affiliates). We have elected to adopt these reduced
disclosure requirements. We cannot predict if investors will find our common stock less attractive as a result of our taking advantage
of these exemptions. If some investors find our common stock less attractive as a result of our choices, there may be a less active trading
market for our common stock and our stock price may be more volatile.

 Pursuant
to Section 107(b) of the JOBS Act, we have elected to use the extended transition period for complying with new or revised accounting
standards under Section 102(b)(2) of The JOBS Act. This election allows us to delay the adoption of new or revised accounting standards
that have different effective dates for public and private companies until those standards apply to private companies. As a result, our
financial statements may not be comparable to companies that comply with public company effective dates. The decision to opt out is irrevocable.

 Because
the worldwide market value of our common stock held by non-affiliates, or public float, was below $250 million on the last day of our
second fiscal quarter, we are also a "smaller reporting company" as defined under the Exchange Act. Some of the foregoing
reduced disclosure and other requirements are also available to us because we are a smaller reporting company and may continue to be
available to us even after we are no longer an emerging growth company under the JOBS Act but remain a smaller reporting company under
the Exchange Act. As a smaller reporting company, we are not required to:

 have an auditor report
 on our internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;

 present more than two years
 of audited financial statements in our registration statements and annual reports on Form 10-K; or

 present any selected financial
 data in such registration statements and annual reports filings made by the Company.

 Shareholders
do not have pre-emptive rights, which will cause them to experience dilution if we issue additional securities.

 At
any time or times, we may issue and sell additional shares of our authorized but previously unissued shares of common stock, preferred
stock, or common stock warrants on such terms and conditions as our Board of Directors, in its sole discretion, may determine without
consent of our shareholders. Our shareholders do not have pre-emptive rights to acquire additional shares should we in the future issue
or sell additional securities. Thus, we are not required to offer any existing shareholder the right to purchase his or her pro rata
portion of any future issuance of securities and, therefore, upon the issuance of any additional securities by us hereafter, our shareholders
will not be able to maintain their then existing pro rata ownership in our outstanding shares of common stock, preferred stock, or common
stock warrants without additional purchases of securities at the price then set internally by us.

 We
are unlikely to pay cash dividends in the foreseeable future.

 We
currently intend to retain any future earnings for use in the operation and expansion of our business. We do not expect to pay any cash
dividends in the foreseeable future but will review this policy as circumstances dictate. Should we decide in the future to do so, as
a holding company, our ability to pay dividends and meet other obligations depends upon the receipt of dividends or other payments from
our operating subsidiaries. In addition, our operating subsidiaries, from time to time, may be subject to restrictions on their ability
to make distributions to us, including as a result of restrictions on the conversion of local currency into U.S. dollars or other hard
currency and other regulatory restrictions.

 Our
insiders own the majority of the outstanding shares of our stock, and accordingly, will have control over stockholder matters, the Company's
business and management.

 One
shareholder, Zhang Liang, owns, in aggregate, common stock representing 51.30% of the outstanding shares of our common stock. While he
continues to hold the majority of the voting power in our Company, he will have effective control over the Company. In particular, he
will have the ability to:

 Elect
or defeat the election of our directors;

 Prevent
amendment of our articles of incorporation or bylaws;

 Prevent
a merger, sale of assets or other corporate transaction; and

 Affect
the outcome of any other matter submitted to the shareholders for vote.

 Moreover,
because of the significant ownership position held by our insiders, new investors will not be able to affect a change in the Company's
business or management, and therefore, shareholders would be subject to decisions made by management and the majority shareholder.

 In
addition, sales of significant amounts of shares held by our directors and executive officers, or the prospect of these sales, could
adversely affect the market price of our common stock. Management's stock ownership may discourage a potential acquirer from making
a tender offer or otherwise attempting to obtain control of us, which in turn could reduce our stock price or prevent our shareholders
from realizing a premium over our stock price.

 Item
1B. Unresolved Staff Comments

 Not
applicable.

 Item 1C. Cybersecurity

 We have established certain processes for identifying,
evaluating, and managing material risks from cybersecurity threats as a part of our overall technology management strategy. These processes
are designed and reassessed on a periodic basis to help protect our technology assets and operations from internal and external security
threats.

 The Company's employees are required to
sign confidentiality agreements in an effort to, among other things, help to ensure cybersecurity. The Company has taken measures to better
ensure that key employees are aware of data security threats (including cybersecurity threats), and Company security policies and procedures,
as appropriate. Improper or illegitimate use of the Company's information system resources or violation of the Company's information
security policies and procedures may result in disciplinary action.

 In the last two fiscal years, we have not identified
cybersecurity threats that have materially affected, or are reasonably likely to materially affect, our business, results of operations,
or financial condition. Although we proactively attempt to prevent all threats, we are unable to eliminate all risk from cybersecurity
threats or provide assurance that we have not experienced an undetected cybersecurity incident. For more information about these risks,
please see Item 1A.

 Item
2. Properties.

 The
Company does not own any real property. We believe the premises we now have under lease will be adequate for our operations for the foreseeable
future.

 Office
Leases

 In October
of 2020, Longduoduo Health Technology entered into an operating cooperation agreement with Baotou Jinshi Traditional Chinese Medicine
Nephropathy Hospital Co., Ltd. Under the terms, Longduoduo Health Technology is able to use its office space (approximately 1000 square
meters) free of charge during the period between October 15, 2020 and October 15, 2025. On March 18, 2021, Longduoduo Health Technology
entered into an assignment agreement with Rongbin, pursuant to which Longduoduo Health Technology transferred all the rights and obligations
under the cooperation agreement to Rongbin, which has been confirmed by Baotou Jin's Traditional Chinese Medicine Nephropathy Hospital
Co., Ltd.

 On March
11 of 2025, Longduoduo Health Technology leased office space (approximately 160 square meters) under an operating lease agreement
with Liu Libao. Under the terms of the agreement, Longduoduo Health Technology is committed to make lease payments of approximately $4,160 (RMB30,000)
for the period between March 11, 2025 and March 10, 2026.

 On April
1 of 2024, Tianju leased office space (approximately 595 square meters) under an operating lease agreement with Sun Xueqin.
Under the terms of the agreement, Tianju is committed to make lease payments of approximately $19,000 (RMB137,000) annually for
the period between April 1, 2024 and March 31, 2027.

 On September 19, 2025, Qingguo leased office
space (approximately 482 square meters) under an operating lease agreement with Chen Mingyue. Under the terms of the agreement, Qingguo
is committed to make lease payments of approximately $30,695 (RMB 220,000) for the period between September 10, 2025 and September 9,
2026.

 On November
20, 2024, Chengheng leased an office space (approximately 611 square meters) under an operating lease agreement from Dongsheng District
Baiyan Health Consultation Department. Under the terms of the agreement, Chengheng is committed to make lease payments of approximately
$16,720 (RMB120,000) for the period between November 20, 2024 and November 20, 2025.

 Item
3. Legal Proceedings.

 From
time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We
are not presently a party to any legal proceedings that in the opinion of our management, if determined adversely to us, would individually
or taken together have a material adverse effect on our business, operating results, financial condition, or cash flows.

 Item
4. Mine Safety Disclosure

 Not
applicable.

 PART
II

 Item
5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 Market
Information

 The
Company's common stock is quoted on the OTCID Market under the symbol "LDDD". The quotations reported on the OTCID
Market reflect inter-dealer prices without retail markup, markdown or commissions, and may not necessarily represent actual transactions.

 The
Company's common stock is thinly traded. The quoted bid and asked prices for the Common Stock vary significantly from week to week.
An investor holding shares of the Company's Common Stock may find it difficult to sell the shares and may find it impossible to
sell more than a small number of shares at the quoted bid price.

 Holders
of Securities

 As
of the date of filing of this report, we had 50 shareholders of record and 30,015,036 outstanding shares of common stock, par value $0.001.

 Dividends

 We
have not declared or paid any cash dividends on our common stock since our inception, and our board of directors currently intends to
retain all earnings for use in the business for the foreseeable future. Any future payment of dividends will depend upon our results
of operations, financial condition, cash requirements and other factors deemed relevant by our board of directors. There are currently
no restrictions that limit our ability to declare cash dividends on our common stock.

 The
PRC government imposes controls on the convertibility of the RMB into foreign currencies and, in certain cases, the remittance of currency
out of China. In addition, each of our subsidiaries in China is required to set aside at least 10% of its after-tax profits each year,
if any, to fund a statutory reserve until such reserve reaches 50% of its registered capital. Each of such entities in China is also
required to further set aside a portion of its after-tax profits to fund the employee welfare fund, although the amount to be set aside,
if any, is determined at the discretion of its board of directors. Although the statutory reserves can be used, among other ways, to
increase the registered capital and eliminate future losses in excess of retained earnings of the respective companies, the reserve funds
are not distributable as cash dividends except in the event of liquidation.

 Securities
Authorized for Issuance Under Equity Compensation Plans

 We
have no equity compensation plans.

 Sales
of Unregistered Securities

 The
Company did not have any unregistered sales of equity securities during the fourth quarter of the fiscal year ended June 30, 2025.

 Repurchase
of Equity Securities

 The
Company did not repurchase any of its equity securities that were registered under Section 12 of the Securities Act during the fiscal
quarter ended June 30, 2025.

 Item
6. [Reserved]

 Item
7. Management's Discussion and Analysis of Financial Condition and Results of Operations

 The
following discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements
and the notes thereto included elsewhere in this Annual Report on Form 10-K, which have been prepared in accordance with accounting principles
generally accepted in the United States. The preparation of such financial statements requires us to make estimates and judgments that
affect the reported amounts of assets, liabilities, revenues, and expenses. On an ongoing basis, we evaluate these estimates, including
those related to useful lives of real estate assets, bad debts, impairment, contingencies and litigation. We base our estimates on historical
experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the
basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There
can be no assurance that actual results will not differ from those estimates. The analysis set forth below is provided pursuant to applicable
SEC regulations and is not intended to serve as a basis for projections of future events. See "Cautionary Statement Regarding Forward
Looking Statements" above.

 Results
of Operations for the Years Ended June 30, 2025 and 2024

 The
following table shows key components of the results of operations during the years ended June 30, 2025 and 2024:

 For the Years Ended

 Change

 2025

 2024

 $

 %

 Total revenue

 $
 4,262,663

 $
 7,389,842

 $
 (3,127,179
)

 (42
)%

 Cost of revenue

 91,099

 173,349

 (82,250
)

 (47
)%

 Gross Profit

 4,171,564

 7,216,493

 (3,044,929
)

 (42
)%

 Total operating expenses

 3,618,885

 5,190,352

 (1,571,467
)

 (30
)%

 Income from operations

 552,679

 2,026,141

 (1,473,462
)

 (73
)%

 Other income (expense)

 161,849

 (139,656
)

 301,505

 (216
)%

 Income before income taxes

 714,528

 1,886,485

 (1,171,957
)

 (62
)%

 Income taxes

 222,268

 523,207

 (300,939
)

 (58
)%

 (871,018
)

 (64
)%

 During
the year ended June 30, 2025, our total revenue was $4,262,663, of which $120,866 was attributable to the sale of healthcare services,
primarily derived from sales of "Immunological Ozonated Autohemotherapy", "Meridian-regulating and Consciousness-restoring
Iatrotechnics", "Assay", "PRP" and other healthcare services. The remaining $4,141,797 of revenue was attributable
to commissions earned by the Company from its service as sales agent for Honghai. In June of 2023, the Company began to engage in the
sales agent business and focused on the sales of preventive healthcare solutions administered by Honghai, with whom we have a Sales Agency
Agreement. As of June 30, 2025, we operate through five entities: Longduoduo Health Technology, Tianju, Qingguo, Rongbin and Chengheng,
which are established in Huhhot, Ulanqab, Huhhot, Baotou and Ordos, respectively, which include four of the largest cities in Inner Mongolia,
China.

 Annual
to annual revenue fell by 42% as compared with the operating revenue of $7,389,842 for the year ended June 30, 2024. The decrease was
primarily attributable to the fact that Inner Mongolia was emerging from the pandemic during the year ended June 30, 2024. A large number
of customers received services during that period that they had earlier paid for but could not receive. This resulted in a surge in revenue
during the year ended June 30, 2024. One other important factor influencing revenue in the recent year is the impact of the economic
environment, which has led to a decrease in customer health expenditures. Management believes that the government has recently introduced
policies to promote economic recovery, but it may take some time for the situation to truly improve. Meanwhile, as we wait for the economy
to revive, the Company is implementing plans to improve its operations by adjusting its operational policies.

 Cost
of revenue relates solely to our healthcare service revenue, and mainly consists of our payments to the third-party healthcare service
providers who perform healthcare services for our customers. During the year ended June 30, 2025, our cost of revenue was $91,099, with
the result that our gross profit from service revenue was $29,767 (a gross margin of 25%). By comparison, our gross profit from healthcare
service revenue for the year ended June 30, 2024 was $154,250, representing 47% of service revenue for that year.

 When
our net service revenue in fiscal year 2025 was combined with commission revenue (for which there is no cost of revenue), we achieved
gross profit of $4,171,564. However, we realized only $552,679 in income from operations for the year ended June 30, 2025 because the
Company incurred significant marketing expense in connection with establishing its brand as a new company. The Company will continue
to invest heavily in advertising and promotion expenses in the near future as it continues to establish and expand its brand and products
and services.

 Our
operating expenses consist primarily of advertising and promotion expenses, salaries and benefits, office expenses, professional fees
and depreciation and amortization. Our operating expenses in fiscal year 2025 decreased by $1,571,467, primarily attributable to:

 $1,942,661
in advertising and promotion expenses incurred in the year ended June 30, 2025, compared to $3,338,737 recorded in the year ended June
30, 2024. The decrease was primarily attributable to the decline in revenue, which we intend to roll over into expanded advertising
and promotion expense for the purpose of achieving a broader market.

 $182,198
in professional fees in the year ended June 30, 2025, compared to $172,337 in recorded in the year ended June 30, 2024. In both cases,
the expense was primarily related to the costs incurred by the Company to establish and sustain its status as an SEC-reporting company
in the United States.

 $580,370
in salaries and benefits expenses in the year ended June 30, 2025, compared to $642,094 in the year ended June 30, 2024. The decrease
in our labor costs was primarily caused by the Company decreasing the number of employees due to adjustments in its operational policies.

 $722,447
in office expenses in the year ended June 30, 2025, compared to $878,968 in the year ended June 30, 2024. The decrease was mainly attributable
to the decline in revenue, which reduced additional administrative services.

 Our
net income for the year ended June 30, 2025 was $492,260, compared to a net income of $1,363,278 in the year ended June 30, 2024.

 Each
of the four subsidiaries of Longduoduo Health Technology has a minority shareholder holding from 10% of its equity (Qingguo) to 49% of
its equity (Tianju). For that reason, we allocate to non-controlling interests the portion of net income corresponding to the minority
interest. After that allocation of $31,825, the net income attributable to common stockholders for the year ended June 30, 2025 was $460,435
(i.e. $0.015 per share). By comparison, for the year ended June 30, 2024 we recorded a net income attributable to common stockholders
of $1,255,448.

 Our reporting currency is the U.S. dollar. Our
functional currency is the local currency, which is the Renminbi (RMB) for our Chinese subsidiaries, the Hong Kong Dollar (HKD) for our
Hong Kong subsidiaries, and the U.S. Dollar (USD) for our BVI subsidiary. Results of operations and cash flow for RMB and HKD are translated
at average exchange rates during the period being reported upon, and assets and liabilities are translated at the unified exchange rate
as quoted by OANDA on the balance sheet date. Translation adjustments resulting from this process are included in other comprehensive
income (loss). For the years ended June 30, 2025 and 2024, foreign currency translation adjustments of $22,921 and $(11,722), respectively,
have been reported as other comprehensive income in the consolidated statement of operations and comprehensive income.

 Liquidity
and Capital Resources

 As
of June 30, 2025, the Company had $1,642,721 in cash and cash equivalents. On the same date, we had a working capital of only $983,123,
primarily because we received $335,484 of deferred revenue from customers as prepayment for future services and products but used the
majority of the deposited sum to pay ongoing expenses and so had only $133,610 in prepayments on our June 30, 2025 balance sheet. Going
forward, we will strive to achieve a better balance of customer deposits and prepayments; but we will achieve that better balance only
when profits from operations and funds from financing are adequate to support the expansion effort that will be necessary for successful
operations.

 We
anticipate that our future liquidity requirements will arise from the need to fund our growth, pay current obligations and future capital
expenditures. The primary sources of funding for such requirements are expected to be cash generated from operations and raising additional
funds from a public offering and/or debt financing. We expect Zhang Liang, our majority shareholder, to continue to provide support in
the future, if needed. However, we can provide no assurances that we will be able to generate sufficient cash flows from operations and/or
obtain additional financing on terms satisfactory to us, if at all, to remain a going concern.

 Cash
Flows

 The
following table summarizes our cash flows for the years ended June 30, 2025 and 2024.

 For the Years Ended

 Change

 2025

 2024

 $

 Net cash provided by operating activities

 $
 277,365

 $
 582,282

 $
 (304,917
)

 Net cash used in investing activities

 (59,375
)

 (305,495
)

 246,120

 Net cash provided by (used in) financing activities

 -

 -

 -

 Effect of exchange rate fluctuation on cash and cash equivalents

 20,689

 (9,307
)

 29,996

 Net increase in cash and cash equivalents

 238,679

 267,480

 (28,801
)

 Cash and cash equivalents, beginning of year

 1,136,562

 267,480

 Cash and cash equivalents, end of year

 $
 1,642,721

 $

 $
 238,679

 Net
Cash Provided by Operating Activities

 For
the year ended June 30, 2025, we had cash provided by operating activities of $277,365, compared to $582,282 for the year ended June
30, 2024. Cash provided by operations during the year ended June 30, 2025 was primarily due to recording net income of $492,260, which
was partially offset by deferred revenue.

 Net
Cash Used in Investing Activities

 Net
cash used in investing activities for the year ended June 30, 2025 was $59,375, compared to $305,495 for the year ended June 30, 2024.
In both periods, the cash was used for the purchase of fixed assets and office decoration.

 Net
Cash Provided by Financing Activities

 Net
cash used in financing activities for the years ended June 30, 2025 and 2024 was $0.

 Critical
Accounting Policies

 The
discussion and analysis of the Company's financial condition and results of operations is based upon its consolidated financial
statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these
financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses, and related disclosure of contingent assets and liabilities. These items are monitored and analyzed by management
for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are recorded
in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that
we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions
do not turn out to be substantially accurate.

 In
our preparation of the financial statements for the year ended June 30, 2025, there was no estimate made which was (a) subject to a high
degree of uncertainty and (b) material to our results.

 Trends,
Events and Uncertainties

 The
U.S. government, including the SEC, has made statements and taken actions that have led to changes in relations between the U.S. and
China, and will impact companies with connections to the United States or China. Those actions by the U.S. government included imposing
several rounds of tariffs affecting certain products manufactured in China and imposing sanctions and restrictions in relation to China.
Actions by the SEC included issuing statements indicating that it would make enhanced review of companies with significant China-based
operations. It is unknown whether and to what extent new legislation, executive orders, tariffs, laws or regulations will be adopted,
or the effect that any such actions would have on U.S.-domiciled companies with significant connections to China, our industry or on
us. Any unfavorable government policies on cross-border relations, including increased scrutiny on companies with significant China-based
operations, capital controls or tariffs, may affect our ability to raise capital and the market price of our shares. If any new legislation,
executive orders, tariffs, laws and/or regulations are implemented, if existing trade agreements are renegotiated or if the U.S. or Chinese
governments take retaliatory actions due to the recent U.S.-China tensions, such changes could have an adverse effect on our business,
financial condition and results of operations, our ability to raise capital and the market price of our shares. Changes in United States
and China relations and/or regulations may adversely impact our business, our operating results, our ability to raise capital and the
market price of our shares.

 Other
than the factors listed above we do not know of any trends, events or uncertainties that have had or are reasonably expected to have
a material impact on our net sales or revenues or income from continuing operations.

 Recent
Accounting Pronouncements

 There
were no recent accounting pronouncements that we expect to have a material effect on the Company's financial position or results
of operations. Please refer to Note 2 of our consolidated financial statements included in this annual report.

 Item
7A. Quantitative and Qualitative Disclosures about Market Risk.

 Not
applicable.

 Item 8.
Financial Statements and Supplementary Data.

 TABLE
OF CONTENTS

 Page

 Years Ended June 30,
 2025 and 2024

 Report of Independent Registered Public Accounting Firm (PCAOB ID 6797)

 Consolidated Balance Sheets as of June 30, 2025 and 2024

 Consolidated Statements of Operations and Comprehensive Income for the years ended June 30, 2025 and 2024

 Consolidated Statement of Changes in Shareholders' Equity (Deficit) for the years ended June 30, 2025 and 2024

 Consolidated Statements of Cash Flows for the years ended June 30, 2025 and 2024

 Notes to Consolidated Financial Statements

 F- 1

 REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 To the Board of Directors and Shareholders of

 Longduoduo Company Limited

 OPINION ON THE FINANCIAL STATEMENTS

 We have audited the accompanying consolidated balance sheets of Longduoduo Company Limited and its subsidiaries (the "Company")
as of June 30, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, stockholders' equity
and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In
our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2025
and 2024, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally
accepted in the United States of America.

 BASIS FOR OPINION

 These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.

 /s/ Bush & Associates CPA LLC

 We have served as the Company's auditor since 2024.

 Henderson, Nevada

 September 26, 2025

 PCAOB
ID Number 6797

 F- 2

 CONSOLIDATED
BALANCE SHEETS

 As of June 30,

 2025

 2024

 Assets

 Current Assets:

 Cash and cash equivalents

 $
 1,642,721

 $

 Other receivables

 37,256

 131,376

 Prepayments

 133,610

 124,427

 Total current assets

 1,813,587

 1,659,845

 Property and equipment, net

 280,003

 353,486

 Right-of-use assets

 32,906

 50,070

 Total assets

 $
 2,126,496

 $
 2,063,401

 Liabilities and Equity (Deficit)

 Current Liabilities:

 Accounts payable

 $
 399,906

 $
 358,613

 Deferred revenue

 335,484

 713,360

 Accrued expenses

 50,027

 50,107

 Due to related parties

 2,233

 Other payables

 -

 35,660

 Operating lease liabilities, current

 18,570

 17,618

 Other current liabilities

 26,069

 86,645

 Total current liabilities

 830,464

 1,264,236

 Operating lease liabilities, less current portion

 -

 18,314

 Total liabilities

 830,464

 1,282,550

 Equity (Deficit):

 Preferred stock; $ 0.001 par value, 30,000,000 shares authorized, no shares issued and outstanding at June 30, 2025 and 2024

 -

 -

 Common stock; $ 0.001 par value, 500,000,000 shares authorized; 30,015,036 and 30,005,016 shares issued and outstanding at June 30, 2025 and 2024, respectively

 30,015

 30,005

 Additional paid-in capital

 7,246,719

 7,246,729

 Accumulated deficit

 ( 6,169,197
)

 ( 6,629,632
)

 Accumulated other comprehensive income

 77,028

 55,413

 Total stockholders' equity

 1,184,565

 702,515

 Non-controlling interests

 111,467

 78,336

 Total stockholders' equity attributable to the common stockholders

 1,296,032

 780,851

 Total liabilities and equity

 $
 2,126,496

 $
 2,063,401

 The
accompanying notes are an integral part of these consolidated financial statements.

 F- 3

 CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

 For the Years Ended

 2025

 2024

 Revenues:

 Service revenue

 $
 120,866

 $
 327,599

 Commission revenue

 4,141,797

 7,062,243

 Total revenues

 4,262,663

 7,389,842

 Cost of revenue:

 Cost of service revenue

 91,099

 173,349

 Total cost of revenues

 91,099

 173,349

 Gross profit

 4,171,564

 7,216,493

 Selling, general and administrative expenses

 3,618,885

 5,190,352

 Income from operations

 552,679

 2,026,141

 Other income (expense)

 161,849

 ( 139,656
)

 Income before provision for income taxes

 714,528

 1,886,485

 Provision for income taxes

 222,268

 523,207

 Less: net income attributable to non-controlling interests

 31,825

 107,830

 Net income attributable to common stockholders

 $
 460,435

 $
 1,255,448

 Comprehensive income:

 $

 $

 Foreign currency translation adjustment

 22,921

 ( 11,772
)

 Comprehensive income

 515,181

 1,351,506

 Less: comprehensive income attributable to non-controlling interests

 33,131

 107,034

 Comprehensive income attributable to the common stockholders

 $
 482,050

 $
 1,244,472

 Basic and diluted income per share

 $
 0.015

 $
 0.042

 Weighted average number of shares outstanding - basic and diluted

 30,009,878

 30,005,016

 The
accompanying notes are an integral part of these consolidated financial statements.

 F- 4

 CONSOLIDATED
STATEMENTS OF CHANGES IN EQUITY (DEFICIT)

 FOR

 Common stock

 Additional

 Accumulated
 Other

 Total
 Stockholder'

 Non-

 Total

 Number of
 Shares

 Amount

 Paid-in
 Capital

 Accumulated
 Deficit

 Comprehensive
 Income

 Equity
 (Deficit)

 controlling
 Interests

 Equity
 (Deficit)

 Balance at June 30, 2023

 30,005,008

 $
 30,005

 $
 7,246,729

 $
 ( 7,885,080
)

 $
 66,389

 $
 ( 541,957
)

 $
 ( 28,698
)

 $
 ( 570,655
)

 Adjustment for the reverse stock split

 -

 -

 -

 -

 -

 -

 -

 -

 -

 -

 1,255,448

 -

 1,255,448

 107,830

 Foreign currency translation adjustment

 -

 -

 -

 -

 ( 10,976
)

 ( 10,976
)

 ( 796
)

 ( 11,772
)

 Balance at June 30, 2024

 30,005,016

 $
 30,005

 $
 7,246,729

 $
 ( 6,629,632
)

 $
 55,413

 $
 702,515

 $
 78,336

 $
 780,851

 Stock issued and exchanged for shares of LDD

 10,020

 ( 10
)

 -

 -

 -

 -

 -

 -

 -

 -

 460,435

 -

 460,435

 31,825

 Foreign currency translation adjustment

 -

 -

 -

 -

 21,615

 21,615

 1,306

 22,921

 Balance at June 30, 2025

 30,015,036

 $
 30,015

 $
 7,246,719

 $
 ( 6,169,197
)

 $
 77,028

 $
 1,184,565

 $
 111,467

 $
 1,296,032

 The
accompanying notes are an integral part of these consolidated financial statements

 F- 5

 CONSOLIDATED
STATEMENTS OF CASH FLOWS

 For the Years Ended

 2025

 2024

 Cash Flows from Operating Activities

 $

 $

 Adjustments to reconcile net income to net cash provided by operating activities:

 Depreciation

 137,290

 102,032

 Loss on disposal of fixed assets

 -

 10,070

 Operating lease expense

 63,345

 58,790

 Changes in operating assets and liabilities:

 Other receivables

 95,330

 ( 24,702
)

 Prepayments

 ( 53,139
)

 ( 114,643
)

 Inventories

 -

 Due from related parties

 20,092

 ( 5,016
)

 Accounts payable

 36,036

 ( 689,296
)

 Deferred revenue

 ( 385,316
)

 126,980

 Accrued expenses

 ( 776
)

 ( 40,922
)

 Due to related parties

 ( 11,462
)

 ( 100,902
)

 Security deposits

 -

 ( 54,992
)

 Other payables

 ( 35,922
)

 ( 48,940
)

 Payment of operating lease liabilities

 ( 18,990
)

 ( 14,250
)

 Other current liabilities

 ( 61,383
)

 13,965

 Net cash provided by operating activities

 277,365

 582,282

 Cash Flows from Investing Activities

 Purchase of property, plant and equipment

 ( 59,375
)

 ( 305,495
)

 Net cash used in investing activities

 ( 59,375
)

 ( 305,495
)

 Cash Flows from Financing Activities

 Proceeds from short-term borrowing from third party

 -

 -

 Net cash (used in) Financing Activities

 -

 -

 Effect of exchange rate fluctuation on cash and cash equivalents

 20,689

 ( 9,307
)

 Net increase in cash and cash equivalents

 238,679

 267,480

 Cash and cash equivalents, beginning of year

 1,136,562

 Cash and cash equivalents, end of year

 $
 1,642,721

 $

 Supplemental Non-Cash Investing and Financing Activities

 Share issuance for acquisition

 $
 -

 $
 -

 Share issuance in exchange for equipment

 $
 -

 $
 -

 Right-of-use assets obtained in exchange for new operating lease liabilities

 $
 -

 $
 -

 Supplemental disclosure of cash flow information

 Cash paid for income taxes

 $
 231,580

 $
 523,207

 Cash paid for interest expense

 $
 -

 $
 -

 The
accompanying notes are an integral part of these consolidated financial statements.

 F- 6

 NOTES

 FOR

 NOTE
1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Company Limited ("Longduoduo", together as a group with Longduoduo's subsidiaries referred to as the "Company"
or "we") was incorporated in the State of Nevada on October 25, 2021. Acting in a principal capacity, the Company provides
customers comprehensive and high-quality preventive healthcare solutions including a wide range of preventive healthcare services, including
disease screening healthcare treatment, healthcare products and other services through a network of third-party healthcare service providers.
In June 2023, the Company began to engage in agent sales of preventive healthcare solutions on behalf of a third-party provider and earn
commissions revenue.

 On
September 21, 2023, the Company implemented a 1-for-10 reverse split of its outstanding common stock, effective at the close of business
on September 26, 2023. The accompanying financial statements have been adjusted to retroactively reflect this reverse stock split.

 Longduoduo's
subsidiaries include:

Company Limited (Hong Kong) ("Longduoduo HK"), was established on July 26, 2021 under the laws of Hong Kong. On October
26, 2021, Longduoduo issued 30,000,000 shares of its common stock to the original shareholders of Longduoduo HK, in exchange for 100 %
of the outstanding shares of Longduoduo HK.

 LDD
Technology Limited ("LDD") was established on March 18, 2024 under the laws of British Virgin Islands. On February 19, 2025,
Longduoduo issued 10,020 shares of its common stock to the original shareholders of LDD, in exchange for 100 % of the outstanding shares
of LDD.

 LDDJK
Hong Kong Limited ("LDDJK") was established on April 9, 2024 under the laws of Hong Kong. LDD has controlled 100 % of LDDJK
since its inception.

 Beijing
Julong Health Consulting Co., Limited ("Julong") was established in Beijing, China on July 23, 2024. LDDJK has controlled
 100 % of Julong since its inception.

 Beijing
Yihua Health Consulting Co., Limited ("Yihua") was established in Beijing, China on March 14, 2024. On January 7, 2025, Julong
acquired all the shares held by the original shareholders of Yihua, and controlled 100 % ownership of Yihua.

Health Technology Company Limited ("Longduoduo Health Technology") is a privately held Limited Company, registered in Inner
Mongolia, China on August 20, 2020. On August 16, 2021, Longduoduo HK acquired 100 % of Longduoduo Health Technology from the original
shareholders of Longduoduo Health Technology. On April 2, 2025, Julong acquired 100 % of Longduoduo Health Technology from Longduoduo
HK.

 Inner
Mongolia Qingguo Health Consulting Company Limited ("Qingguo") is a privately held Limited Company, registered in Inner Mongolia,
China on June 18, 2020. On September 8, 2020, Longduoduo Health Technology acquired 90 % of Qingguo from the original shareholders of
Qingguo.

 Inner
Mongolia Rongbin Health Consulting Company Limited ("Rongbin") is a privately held Limited Company, registered in Inner Mongolia,
China on March 18, 2021. Longduoduo Health Technology has controlled 80 % of Rongbin since its inception.

 Inner
Mongolia Chengheng Health Consulting Company Limited ("Chengheng") is a privately held Limited Company, registered in Inner
Mongolia, China on April 9, 2021. Longduoduo Health Technology has controlled 80 % of Chengheng since its inception.

 Inner
Mongolia Tianju Health Consulting Company Limited ("Tianju") is a privately held Limited Company registered in Inner Mongolia,
China on July 5, 2021. Longduoduo Health Technology has controlled 51 % of Tianju since inception.

 The
transactions summarized above are treated in the Company's financial statements as a corporate restructuring (reorganization) of
entities under common control, as each of the eleven entities have at all times been under the control of Mr. Zhang Liang. Therefore,
in accordance with ASC 805-50-45-5, the current capital structure has been retroactively presented in prior periods as if such structure
existed at that time, and the entities under common control are presented on a combined basis for all periods. Since all of the subsidiaries
were under common control for all periods presented, the results of these subsidiaries are included in the Company's financial
statements for all periods presented.

 F- 7

 NOTES

 FOR

 NOTE
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 A.
Basis of presentation

 The
accompanying consolidated financial statements are expressed in U.S. Dollars and have been prepared on the accrual basis of accounting
in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

 B.
Principles of consolidation

 The consolidated financial statements include
the accounts of Longduoduo and its subsidiaries. All significant inter-company accounts and transactions have been eliminated. The consolidated
financial statements include 100 % of assets, liabilities, and net income of these subsidiaries.

 LDD Technology Limited was established on March
18, 2024 under the laws of British Virgin Islands. LDD is a holding company with no business operations of its own. On February 19, 2025,
Longduoduo issued 10,020 shares of its common stock to the original shareholders of LDD, and assumed all the original shareholders' capital
contribution obligations of LDD, in exchange for 100 % of the outstanding shares of LDD. This transaction is treated in the Company's
financial statements as a corporate restructuring (reorganization) of entities under common control, as LDD and Longduoduo have at all
times been under the control of Mr. Zhang Liang. Therefore, this transaction is accounted for by the carry-over basis method (also referred
to as the pooling-of-interests method or historical-cost method). The assets and liabilities transferred are recorded by the receiving
entity at their historical carrying amounts in the consolidated financial statements of the controlling parent, not at fair value. No
new goodwill is recognized, and no gain or loss is recorded. In accordance with ASC 805-50-45-5, the current capital structure has been
retroactively presented in prior periods as if such structure existed at that time, and the entities under common control are presented
on a combined basis for all periods. Since LDD and Longduoduo were under common control for all periods presented, the results of LDD
are included in the Company's financial statements for all periods presented.

 Longduoduo's
subsidiaries as of June 30, 2025 are listed as follows:

 Name

 Place of
 Incorporation

 Attributable
 equity
 interest %

 Authorized
 capital

 Longduoduo Company Limited

 Hong Kong

 HK$
 10,000

 LDD Technology Limited

 British Virgin Islands

 $
 100,000

 LDDJK Hong Kong Limited

 Hong Kong

 HK$
 10,000

 Beijing Julong Health Consulting Co., Limited

 China

 Beijing Yihua Health Consulting Co., Limited

 China

 Longduoduo Health Technology Company Limited

 China

 Inner Mongolia Qingguo Health Consulting Company Limited

 China

 Inner Mongolia Rongbin Health Consulting Company Limited

 China

 Inner Mongolia Chengheng Health Consulting Company Limited

 China

 Inner Mongolia Tianju Health Consulting Company Limited

 China

 C.
Use of estimates

 The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements,
and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information
available at the time the estimates are made; however, actual results could differ from those estimates. Significant items subject to
such estimates and assumptions include the inventory valuation allowance and the treatment of the shares issued. These estimates are
often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable.
Actual results could differ from these estimates.

 F- 8

 NOTES

 FOR

 D.
Functional currency and foreign currency translation

 An
entity's functional currency is the currency of the primary economic environment in which it operates, normally that is the currency
of the environment in which the entity primarily generates and expends cash. Management's judgment is essential to determine the
functional currency by assessing various indicators, such as cash flows, sales price and market, expenses, financing and inter-company
transactions and arrangements. The functional currency of the Company is the Chinese Renminbi ("RMB'), except the functional
currency of Longduoduo HK and LDDJK is the Hong Kong Dollar and the functional currency of Longduoduo and LDD is the United States Dollar
("US Dollars" or "$"). The reporting currency of these consolidated financial statements is in US Dollars.

 The
financial statements of Longduoduo's subsidiaries, which are prepared using the RMB and HKD, are translated into the Company's
reporting currency, the US Dollar. Assets and liabilities are translated using the exchange rate at each reporting period end date. Revenue
and expenses are translated using weighted average rates prevailing during each reporting period, and stockholders' equity (deficit)
is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated
other comprehensive income or expense.

 Transactions
denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing
at the dates of the transactions. Foreign currency exchange gains and losses resulting from these transactions are included in operations.

 The
exchange rates used for foreign currency translation are as follows:

 For
 the Years Ended June 30,

 2025

 2024

 (USD to RMB/

 USD to HKD)

 (USD to RMB/

 USD to HKD)

 Assets and
 liabilities

 period end
 exchange rate

 7.1672 / 7.8499

 7.2675 / 7.8081

 Revenue and expenses

 period weighted average

 7.2145 / 7.7895

 7.2107 / 7.8190

 E.
Concentration of credit risk

 The
Company maintains cash in state-owned banks in China. In China, the insurance coverage of each bank is RMB 500,000 (approximately
USD$ 70,000). As of June 30, 2025 and 2024, the Company had $ 1,130,547 and $ 826,853 cash in excess of the insured amount, respectively.

 For
each of the years ended June 30, 2025 and 2024, one customer accounted for 97.2 % and 95.6 % of revenue.

 For
the years ended June 30, 2025 and 2024, the Company had two and three major suppliers, respectively, that accounted for over 10%
of its total cost of revenue.

 Year ended June 30, 2025

 Year ended June 30, 2024

 Cost of
 revenue

 Percentage of
 Cost of
 revenue

 Cost of
 revenue

 Percentage of
 Cost of
 revenue

 Supplier A

 $
 29,666

 %

 $
 57,358

 %

 Supplier B

 38,502

 %

 31,216

 %

 Supplier C

 -

 -

 63,663

 %

 F.
Cash and cash equivalents

 Cash
consists of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. All highly liquid investments with original
stated maturity of three months or less are classified as cash and cash equivalents. Cash equivalents approximate or equal fair value
due to their short-term nature. The Company's cash and cash equivalents consist of cash on hand and cash in bank as of June 30,
2025 and 2024.

 F- 9

 NOTES

 FOR

 G.
Property and equipment

 Property
and equipment are stated at cost. Expenditures for maintenance and repairs are charged to operations when incurred, while additions and
betterments are capitalized. Depreciation is recorded on a straight-line basis over the useful lives of the assets. When assets are retired
or disposed, the asset's original cost and related accumulated depreciation are eliminated from those accounts and any gain or
loss is reflected in income.

 The
Company capitalizes certain costs associated with the acquisition of software. Once the software is ready for its intended use, these
costs are amortized on a straight-line basis over the software's expected useful life.

 The
estimated useful lives for property and equipment categories are as follows:

 Office equipment
 and furniture

 3 years

 Leasehold Improvements

 1 - 5 years

 H.
Intangible Assets

 Intangible
assets consist of software. Intangible assets are initially recognized at their respective acquisition costs. All of the Company's
intangible assets have been determined to have finite useful lives and are, therefore, amortized using the straight-line method over
their estimated useful lives:

 Software

 3 years

 I.
Fair value measurements

 The
Company applies the provisions of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC")
Section 820, Fair Value Measurements ("ASC 820"), for fair value measurements of financial assets and financial
liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.
ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.

 Fair
value is defined as the price that would be received when selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. In determining the fair value for the assets and liabilities required or permitted
to be recorded, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions
that market participants would use when pricing the asset or liability.

 ASC
820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives
the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the
lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value
hierarchy are as follows:

 Level
1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

 Level
2: Quoted prices, other than those in Level 1, in markets that are not active, or inputs that are observable, either directly or indirectly,
for substantially the full term of the asset or liability,

 Level
3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported
by little or no market activity).

 There
were no transfers between level 1, level 2 or level 3 measurements for the years ended June 30, 2025 and 2024.

 Financial
assets and liabilities of the Company are primarily comprised of cash and cash equivalents, other receivables, prepayments, due from
related parties, accounts payable, deferred revenue, accrued expenses, due to related parties and other payables. As of June 30, 2025
and 2024, the carrying values of these financial instruments approximated their fair values due to the short-term maturity of these instruments.

 F- 10

 NOTES

 FOR

 J.
Segment information and geographic data

 The
Company is operating in one segment in accordance with the accounting guidance in FASB ASC Topic 280, Segment Reporting.
The company's revenues are from customers in the People's Republic of China ("PRC"). Substantially all assets
of the Company are located in the PRC.

 K.
Revenue recognition

 The
Company adopted FASB ASC Section 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from
the sales of products and services by applying the following steps: (1) identify the contract with a customer; (2) identify the performance
obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in
the contract; and (5) recognize revenue when each performance obligation is satisfied.

 The
Company recognizes revenue when the amount of revenue can be reliably measured, it is probable that economic benefits will flow to the
entity, and specific criteria have been met for each of the Company's activities as described below.

 Service
Revenue

 The
Company sells healthcare service packages to customers, which represent the rights to services purchased by the Company. The delivery
of a healthcare service package to a customer represents a separate performance obligation. The Company's policy is to recognize
service revenue at that time when the healthcare service package has been sold, ownership and risk of loss have been transferred to the
customer, and the service has been provided. Accordingly, revenue is recognized at the point in time when the service is provided. Service
revenue is recognized when the healthcare service package has been delivered to the customer and there are no remaining performance obligations.

 Management
regularly reviews the sales returns and allowances based on historical experience. Any subsequent sales returns and cancellations are
recognized upon notification from the customers. The liability for sales returns and allowances relating to the sale of healthcare service
packages amounted to $ 208 and $ 923 as of June 30, 2025 and June 30, 2024, respectively. Management's provision for sales
returns and allowances was 1.60 % and 1.13 %, respectively, of the total service revenue for the years ended June 30, 2025 and
2024.

 The
Company typically collects fees before delivery of healthcare packages. Amounts received from a customer before the delivery of the healthcare
package are recorded as deferred revenue on the Consolidated Balance Sheets.

 Commission
Revenue

 Commencing
in the three months ended June 30, 2023, the Company started offering in a sales agent capacity healthcare service and product packages
of a third-party provider. The third party is responsible for fulfillment of the services to the customer and the Company has no performance
commitment or liability to the customer. The Company receives deposits from the customers, remits to the third-party provider the provider's
contracted amounts, and retains the remaining amounts as commission revenue. The commission revenue is recognized upon acceptance of
the customer contract by the third-party provider and is presented on a net basis in the Statement of Operations and Comprehensive Income.

 Cost
of Revenues

 Cost
of service revenue consists primarily of the cost of healthcare service packages purchased from third party healthcare service providers
to fulfill contracts with customers.

 Cost
of product revenue consists primarily of the cost of healthcare products purchased from suppliers. Cost of product revenue is recognized
when the product has been delivered to the customer.

 F- 11

 NOTES

 FOR

 L.
Income taxes

 The
Company follows FASB ASC Section 740, Income Taxes, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method,
deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities
and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods
in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred
tax assets to the amount expected to be realized.

 ASC
740-10-30 requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements.
Under ASC 740-10-30, tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first
subsequent financial reporting period in which that threshold is met.

 The
application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations
themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court
rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional
tax liabilities or potentially reverse previously recorded tax liabilities or the deferred tax asset valuation allowance.

 As
a result of the implementation of ASC 740-10, the Company made a comprehensive review of its portfolio of tax positions in accordance
with recognition standards established by ASC 740-10. The Company recognized no material adjustments to liabilities or shareholder's
equity as a result of the implementation.

 M.
Earnings (loss) per share

 The
Company computes earnings (loss) per share ("EPS") in accordance with ASC 260, Earnings Per Share. ASC 260 requires
companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income (loss) divided by the
weighted average common shares outstanding during the period.

 Diluted
EPS is similar to basic EPS but presents the dilutive effect on a per share basis of contracts to issue common shares (e.g., convertible
securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later.
The computation of diluted EPS includes the estimated impact of the exercise of contracts to purchase common stock using the treasury
stock method and the potential shares of converted common stock associated with the convertible debt using the if-converted method. Potential
common shares that have an anti-dilutive effect (i.e., those that increase earnings per share or decrease loss per share) are excluded
from the calculation of diluted EPS.

 On
February 19, 2025, Longduoduo issued 10,020 shares of its common stock to the original shareholders of LDD, in exchange for 100 % of the
outstanding shares of LDD.

 N.
Recently adopted accounting pronouncements

 We
do not believe that any recently issued but not yet effective accounting standards, if currently adopted, would have a material effect
on the Company's consolidated financial position, statements of operations and cash flows.

 NOTE
3. PREPAYMENTS

 Prepayments
primarily include prepaid expenses, equipment, leasing and products in advance to suppliers. As of June 30, 2025 and 2024, prepayments
and deferred expenses were $ 133,610 and $ 124,427, respectively.

 F- 12

 NOTES

 FOR

 NOTE
4. PROPERTY AND EQUIPMENT

 At
June 30, 2025 and 2024, property and equipment, at cost, consisted of:

 2025

 2024

 Office equipment and furniture

 $
 452,187

 $
 461,562

 Leasehold improvement

 70,404

 40,506

 Total

 522,591

 502,068

 Accumulated depreciation

 242,588

 148,582

 Total property and equipment, net

 $
 280,003

 $
 353,486

 The
Company recorded depreciation expense of $ 137,290 for the year ended June 30, 2025, of which $ 127,864 was recorded
as operating expense and $ 9,426 was recorded as cost of revenue.

 The
Company recorded depreciation expense of $ 102,032 for the year ended June 30, 2024, of which $ 92,492 was recorded
as operating expense and $ 9,540 was recorded as cost of revenue.

 The
Company disposed of fully depreciated assets with a total value of $ 46,271 for the year ended June 30, 2025.

 NOTE
5. RELATED PARTY TRANSACTIONS

 Due
to related parties

 Due
to related parties consists of the following:

 Name of related party

 2025

 2024

 Zhang Liang

 $

 $
 2,233

 Total

 $

 $
 2,233

 Until
November 29, 2023, Zhang Liang was the President and Chairman of the Board of Longduoduo. Mr. Zhang Liang controls approximately 51.3 %
of Longduoduo's issued and outstanding common stock. These advances due to related parties are unsecured, repayable on demand,
and bear no interest.

 Related parties' transactions

 Related parties' transactions consists of
the following:

 Name of related parties

 2025

 2024

 Zhang Liang

 $
 8,630

 $
 ( 105,918
)

 Total

 $
 8,630

 $
 ( 105,918
)

 NOTE
6. INCOME TAXES

 United
States

is subject to the U.S. corporation tax rate of 21 %.

 British Virgin Islands

 The Company' subsidiary, LDD, is incorporated
in the BVI and is not subject to tax on income or capital gain. In addition, payments of dividends by LDD to its shareholders are not
subject to withholding tax in the BVI.

 Hong
Kong

 Longduoduo HK and LDDJK are incorporated in Hong
Kong and are subject to Hong Kong profits tax. They are subject to Hong Kong taxation on its activities conducted in Hong Kong and income
arising in or derived from Hong Kong. From year of assessment of 2019/2020 onwards, Hong Kong profits tax rates are 8.25 % on assessable
profits up to HK$ 2,000,000, and 16.5 % on any part of assessable profits over HK$ 2,000,000. The Company did not have any income (loss)
subject to the Hong Kong profits tax.

 F- 13

 NOTES

 FOR

 China

 Julong and its subsidiaries are subject to a 25 %
standard enterprise income tax in the PRC. If the taxable income in the calendar year does not exceed RMB 3 million, only 25 % of the
taxable income will be included in the tax base, which is then subject to a preferential tax rate of 20 %. The Company accrued $ 222,268
and $ 523,207 of PRC income tax for the years ended June 30, 2025 and 2024.

 A
summary of income (loss) before income taxes for domestic and foreign locations for the years ended June 30, 2025 and 2024 is as follows:

 2025

 2024

 United States

 $
 ( 219,614
)

 $
 ( 200,515
)

 Foreign

 934,142

 2,087,000

 Total Income before income taxes

 $
 714,528

 $
 1,886,485

 The
difference between the U.S. federal statutory income tax rate and the Company's effective tax rate was as follows:

 2025

 2024

 Income tax (benefit) at USA statutory rate

 %

 %

 U.S. valuation allowance

 ( 21
)%

 ( 21
)%

 Income tax (benefit) at USA effective rate

 %

 %

 The
difference between the PRC statutory income tax rate and the PRC effective tax rate was as follows:

 2025

 2024

 Income tax (benefit) at PRC statutory rate

 %

 %

 Utilization of net operating loss carry forward

 -

 ( 1
)%

 Tax preference

 ( 10.2
)%

 -

 PRC valuation allowance

 %

 %

 Income tax (benefit) at PRC effective rate

 17.8
 %

 %

 The Company did not recognize deferred tax assets
since it is not more likely than not that it will realize such deferred taxes. The deferred tax would apply to Longduoduo in the U.S.
and Julong and subsidiaries in China.

 As of June 30, 2025, Julong and its subsidiaries had total net operating
loss carry forwards of approximately $ 414,846 in the PRC that expire through 2030. Due to the uncertainty of utilizing these carry
forwards, the Company provided a 100 % allowance on all deferred tax assets of approximately $ 103,712 and $ 9,696 related to
its operations in the PRC as of June 30, 2025 and 2024, respectively. The PRC valuation allowance has increased by $ 94,016 and
decreased by $ 77,798 for the years ended June 30, 2025 and 2024, respectively.

 The
Company incurred losses from its United States operations during the year ended June 30, 2025 of approximately $ 219,614. The Company's
United States operations consist solely of ownership of its foreign subsidiaries, and the losses arise from administration expenses.
Accordingly, management provided a 100 % valuation allowance of approximately $ 259,555 and $ 199,817 against the deferred
tax assets related to the Company's United States operations as of June 30, 2025 and 2024, respectively, because the deferred tax
benefits of the net operating loss carry forwards in the United States are not likely to be utilized. The US valuation allowance has
increased by approximately $ 59,738 and $ 28,490 for the years ended June 30, 2025, and 2024, respectively.

 The
Company is subject to examination by the Internal Revenue Service (IRS) in the United States as well as by the taxing authorities in
China, where the Company has significant business operations. The table below presents the earliest tax year that remains subject
to examination by major jurisdiction.

 Earliest tax year that
 remains subject to examination

 U.S. Federal

 June 30, 2021

 China

 June 30, 2020

 NOTE
7. LEASES

 On
April 1 of 2024, Tianju leased office space (approximately 595 square meters) under an operating lease agreement with Sun Xueqin. Under
the terms of the agreement, Tianju is committed to make lease payments of approximately $ 19,000 (RMB 137,000) annually for the period
between April 1, 2024 and March 31, 2027.

 F- 14

 NOTES

 FOR

 On August 14, 2024, Qingguo leased office space
(approximately 482 square meters) under an operating lease agreement with Inner Mongolia Chuangfuhui Enterprise Management
Co., Ltd. Under the terms of the agreement, Qingguo was committed to make lease payments of approximately $ 30,700 (RMB 220,000)
for the period between September 10, 2024 and September 9, 2025. On September 19, 2025, Qingguo with Chen Mingyue signed an agreement
leased this office space under non-cancellable operating lease agreements. Under terms of the lease agreement, from September 10, 2025,
Qingguo is committed to make lease payments of approximately $ 30,695 per year for 1 year.

 On
November 20, 2024, Chengheng leased an office space (approximately 611 square meters) under an operating lease agreement from Dongsheng
District Baiyan Health Consultation Department. Under the terms of the agreement, Chengheng is committed to make lease payments of approximately
$ 16,700 (RMB 120,000) for the period between November 20, 2024 and November 20, 2025.

 On
March 11 of 2025, Longduoduo Health Technology leased office space (approximately 160 square meters) under an operating lease agreement
with Liu Libao. Under the terms of the agreement, Longduoduo Health Technology is committed to make lease payments of approximately $ 4,200
(RMB 30,000) for the period between March 11, 2025 and March 10, 2026.

 Leases
with an initial term of 12 months or less are not recorded on the balance sheet. Operating lease cost is recognized as a single lease
cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. For lease agreements
entered into or reassessed after the adoption of Topic 842, the Company did not combine lease and non-lease components.

 Most leases do not include options to renew.
The exercise of lease renewal options has to be agreed to by the lessors. The depreciable life of assets and leasehold improvements are
limited by the term of leases, unless there is a transfer of title or purchase option reasonably certain of exercise. Lease expense is
recognized on a straight-line basis over the term of the lease. Lease expense related to these noncancelable operating leases was $ 63,345 and
$ 58,790 for the years ended June 30, 2025 and 2024, respectively.

 Balance
sheet information related to the Company's leases is presented below:

 2025

 2024

 Assets

 Operating lease right of use assets

 $
 32,906

 $
 50,070

 Liabilities

 Operating lease liabilities – current

 $
 18,570

 $
 17,618

 Operating lease liabilities – non-current

 -

 18,314

 Total Operating lease liabilities

 $
 18,570

 $
 35,932

 Other
information related to leases is presented below:

 2025

 2024

 Cash Paid for Amounts Included in Measurement of Liabilities:

 Operating cash flows used in operating leases

 $
 18,990

 $
 14,250

 Weighted Average Remaining Lease Term:

 Operating leases

 1.75 years

 2.75 years

 Weighted Average Discount Rate

 Operating leases

 3.95
 %

 3.95
 %

 As
most of the Company's leases do not provide an implicit rate, the Company uses 1 - 5 years borrowing rate from bank of 3.95 %
based on the information available at commencement date in determining the present value of lease payments.

 Maturities
of lease liabilities are as follows:

 For the year ending June 30:

 2026

 $
 19,115

 Total lease payments

 19,115

 Less: imputed interest

 ( 545
)

 Total lease liabilities

 $
 18,570

 F- 15

 NOTES

 FOR

 NOTE
8. CONTINGENCIES

 Contingencies

 Certain
conditions may exist as of the date the consolidated financial statements are issued which may result in a loss to the Company but which
will only be resolved when one or more future events occur or fail to occur. The Company's management and legal counsel assess
such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related
to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's
legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount
of relief sought or expected to be sought.

 If
the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability
can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates
that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the
nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed.

 Loss
contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee
would be disclosed.

 The
Company was not subject to any material loss contingency as of June 30, 2025 and 2024.

 NOTE
9. STOCKHOLDERS' EQUITY

 On
September 21, 2023, the Company filed with the Nevada Secretary of State a Certificate of Change Pursuant to NRS 78.209. The Certificate
of Change provided for a 1-for-10 reverse split of the Registrant's outstanding common stock effective at the close of business
on September 26, 2023. The Certificate of Change did not change the number of authorized shares of Common Stock, which remains 500,000,000
shares. No fractional shares were issued in connection with the reverse stock split; any fractional shares that resulted from the reverse
split were rounded up to the nearest whole share. The accompanying financial statements have been adjusted to retroactively reflect this
reverse stock split.

 Share
exchange under common control

 On
February 19, 2025, Longduoduo issued 10,020 shares of its common stock to the original shareholders of LDD, in exchange for 100 % of the
outstanding shares of LDD. This transaction is treated as a corporate restructuring (reorganization) of entities under common control,
as each of the entities have at all times been under the control of Mr. Zhang Liang.

 F- 16

 NOTES

 FOR

 NOTE
10. BASIC AND DILUTED EARNINGS PER SHARE

 Basic net income per share is computed using
the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted
average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares comprise
shares issuable upon the exercise of share-based awards, using the treasury stock method. The reconciliation of the numerators and
denominators of the basic and diluted earnings per share computations is shown as follows:

 2025

 2024

 Numerator:

 Net income attributable to common stockholders

 $
 460,435

 $
 1,255,448

 Denominator:

 Basic and diluted weighted-average number of shares outstanding

 30,009,878

 30,005,016

 Net income per share:

 Basic and diluted

 $
 0.015

 $
 0.042

 NOTE
11. NON-CONTROLLING INTERESTS

 Qingguo,
Chengheng, Rongbin and Tianju are the Company's majority-owned subsidiaries which are consolidated in the Company's financial
statements with non-controlling interests recognized. The Company holds 90 %, 80 %, 80 % and 51 % interest of Qingguo,
Chengheng, Rongbin and Tianju as of June 30, 2025, respectively.

 As
of June 30, 2025 and 2024, the non-controlling interests in the consolidated balance sheet was $ 111,467 and $ 78,336, respectively.

 For
year ended June 30, 2025, the comprehensive income attributable to common stockholders and non-controlling interests were $ 482,050 and
$ 33,131, respectively.

 For
year ended June 30, 2024, the comprehensive income attributable to common stockholders and non-controlling interests were $ 1,244,472 and
$ 107,034, respectively.

 NOTE
12. SUBSEQUENT EVENTS

 Management
has evaluated subsequent events through the date which the consolidated financial statements were available to be issued. All subsequent
events requiring recognition as of June 30, 2025 have been incorporated into these consolidated financial statements and there are no
subsequent events that require disclosure in accordance with FASB ASC Topic 855, "Subsequent Events."

 F- 17

 Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 None.

 Item
9A. Controls and Procedures.

 Evaluation
of Disclosure Controls and Procedures

 Our
management maintains disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), that are designed to provide reasonable assurance that the material information required
to be disclosed by us in our periodic reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported
within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation,
controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under
the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer,
to allow timely decisions regarding required disclosures.

 Under
the supervision and with the participation of our management team, including our Chief Executive Officer and Chief Financial Officer,
we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and 15d-15(e)
promulgated under the Securities Exchange Act of 1934, as amended, as of June 30, 2025. Based on this evaluation, we concluded that our
disclosure controls and procedures have the following material weaknesses:

 The
relatively small number of employees who are responsible for accounting functions prevents us from segregating duties within our internal
control system.

 Our
internal financial staff lack expertise in identifying and addressing complex accounting issues under U.S. Generally Accepted Accounting
Principles.

 Our
Chief Financial Officer is not familiar with the accounting and reporting requirements of a U.S. public company.

 We
have not developed sufficient documentation concerning our existing financial processes, risk assessment and internal controls.

 Based
on their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the Company's system of disclosure
controls and procedures was not effective as of June 30, 2025 for the purposes described in this paragraph.

 Management's
Report on Internal Control over Financial Reporting

 The
Company's management is responsible for establishing and maintaining adequate internal control over our financial reporting as
defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act. The Company's management is also required to assess
and report on the effectiveness of the Company's internal control over financial reporting in accordance with Section 404 of the
Sarbanes-Oxley Act of 2002 ("Section 404"). Internal control over financial reporting is a process to provide reasonable
assurance regarding the reliability of the Company's financial reporting for external purposes in accordance with generally accepted
accounting principles. Internal control over financial reporting includes policies and procedures that: (i) pertain to maintaining records
that in reasonable detail accurately and fairly reflect the Company's transactions; (ii) provide reasonable assurance that transactions
are recorded as necessary for preparation of the Company's financial statements and that receipts and expenditures of company assets
are made in accordance with management authorization; and (iii) provide reasonable assurance that unauthorized acquisition, use or disposition
of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis.

 Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies and procedures may deteriorate.

 As
of June 30, 2025, our management, under the supervision of and with the participation of the Chief Executive Officer and the Chief Financial
Officer, evaluated the effectiveness of our internal control over financial reporting as required by Rules 13a-15(c) and 15d-15(c) under
the Exchange Act. In making this assessment, Management used the criteria set forth by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO) in Internal Control – Integrated Framework (1992), including the following five framework components:
i) control environment, ii) risk assessment, iii) control activities, iv) information and communications, and v) monitoring. In the course
of making our assessment of the effectiveness of internal controls over financial reporting, we identified four material weaknesses in
our internal control over financial reporting. These material weaknesses consisted of the four material weaknesses identified above under
the heading "Evaluation of Disclosure Controls and Procedures."

 Management
does not believe that the current level of the Company's operations warrants a remediation of the weaknesses identified in this
assessment. However, because of the above condition, management's assessment is that the Company's internal controls over
financial reporting were not effective as of June 30, 2025.

 This
annual report does not include an attestation report of the Company's registered public accounting firm regarding internal control
over financial reporting. The Company's internal control over financial reporting was not subject to attestation by the Company's
registered public accounting firm as we are a smaller reporting company.

 Our
management will continue to monitor and evaluate the effectiveness of its disclosure controls and procedures, as well as its internal
control over financial reporting, on an ongoing basis, and is committed to taking further action and implementing additional improvements,
as necessary and as funds allow. However, our management cannot guarantee that the measures taken or any future measures will remediate
the material weaknesses identified or that any additional material weaknesses or significant deficiencies will not arise in the future
due to a failure to implement and maintain adequate internal control over financial reporting. Notwithstanding the material weaknesses
described above, our management believes that there are no material inaccuracies or omissions of material fact and, to the best of its
knowledge, believes that the consolidated financial statements included in this annual report present fairly, in all material respects,
our financial position, results of operations, and cash flows for the periods presented in conformity with accounting principles generally
accepted in the United States.

in Internal Control over Financial Reporting

 No
changes in the Company's internal control over financial reporting has come to management's attention during the quarter
ended June 30, 2025 that have materially affected, or are likely to materially affect, the Company's internal control over financial
reporting.

 Item
9B. Other Information.

 None.

 Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

 Not
applicable.

 PART
III

 Item
10. Directors, Executive Officers and Corporate Governance.

 Name
 and Address*

 Age

 Position/Title

 Xu
 Huibo

 President
 and Chairman of the Board

 Chief Executive Officer
 and Director

 Wu Binbin

 Shan Bo

 Ma Jiayang

 Chief Financial Officer

 *

 The business address for
 all directors and officers is G3-5-8016, Shui'an Town, Ruyi Headquarte, Hohhot Economic Development District, Hohhot, Inner
 Mongolia, China 010000.

 Xu
Huibo, President and Chairman of the Board

 Xu
Huibo has been engaged in developing business strategies and assisting in their implementation for the past decade. Since 2022, Xu Huibo
has been employed as Chairman and President of Jinrong Holdings (Hainan) Group Co., Ltd., where he was responsible for directing that
company's overall business strategy and operations. Jinrong Holdings operates a number of hospitals, primarily focused on the prevention
of cardiovascular diseases. From 1917 to 2022 Xu Huibo served as Chairman of Fengqi Technology Co., Ltd., which provided business consulting
services to the biotechnology and health management industries. Xu Huibo provided financial management advice to the company's
clients, as well as formulating strategic initiatives appropriate for the client's overall business plan. From 2014 to 2016 Xu
Huibo provided similar services as Chairman of Zhengzhou Suhe Asset Management Co., Ltd., an enterprise management and consulting firm.
In 2006 Mr. Xu was awarded a Bachelor's Degree in Finance by Shandong University.

 Zhou
Hongxiao, Chief Executive Officer and Director

 Ms.
Zhou has served as our Chief Executive Officer ("CEO") and director since the incorporation of the Company. Ms. Zhou was
employed by Tianjin Aike Clothing Co., Ltd. from 2004 to 2016 and served as Marketing Manager. From 2017 to 2019, Ms. Zhou was employed
by Tianyan Tea Industry Co., Ltd. and served as Chief Executive Officer. Ms. Zhou was employed by Longduoduo Health Technology Co., Ltd
as CEO since 2020. Ms. Zhou is familiar with sales management and sales regulations and related laws. She is responsible for business
operations, budget development, analysis and oversight, marketing including volume growth/program development; expense control, policy
and procedure development and implementation, and process development to facilitate regulatory compliance. She is responsible for the
overall operation of Longduoduo. Ms. Zhou brings to the Board her experience in business oversight and financial and budgetary matters.
Ms. Zhou was awarded a bachelor's degree by Inner Mongolia Radio and Television University in 2003. She obtained her Fine Chemical
Industry College degree from Jilin Province Jilin City Institute of Technology in 1998.

 Wu
Binbin, Director.

 Wu
Binbin has been employed through the past decade in financial management and accounting. From 2017 until 2022 Wu Binbin was employed
as Chief Financial Officer of Shenzhen Qianhai Rongsheng Capital Management Co., Ltd., which provides comprehensive financial management
services to its clients. In that position, Mr. Wu specialized in developing executive compensation programs for his firm's clients.
From 2013 until 2016 Mr. Wu was employed as Audit Manager by Henan Ruixiang Certified Public Accountants Co., Ltd., which provides accounting,
audit and tax audit services to its clients. Wu Binbin was licensed as an accountant in China in 2013, having been awarded a Bachelor's
Degree with a concentration in finance and taxation by Henan University of Finance and Economics in 2012.

 Shan
Bo, Director.

 Shan
Bo has been employed during the past twenty years in financial management and accounting. Since 2018 he has served as Chief Financial
Officer for OFILM Group, a manufacturing company that is publicly-held in China. From 2015 until 2018, Shan Bo was employed as Manager
of the Investment Department of China Orient Asset Management Corporation. From 2005 until 2015 Shan Bo was a partner in Zhongxinghua
Certified Public Accountants LLP. Shan Bo will bring to Longduoduo his expertise in both financial management and accounting, but also
corporate strategy and business planning.

 Ma
Jiayang, Director

 Since
September 2019, Ma Jiayang has been employed as a lawyer by the Inner Mongolia Shuoda Law Firm, where she specializes in resolution of
ownership disputes and financial contract disputes. During her tenure at Inner Mongolia Shuoda Law Firm, Ms. Ma has served as legal advisor
to government entities, including the Education Bureau of Baotou City, Shahe South Village and West Village in Erdao, Baotou City, as
well as the Baotou Branch of China Construction Bank. Ma Jiayang graduated from Inner Mongolia University in 2019 with a Bachelor's
degree in law.

 Kang
Liping, Chief Financial Officer

 Ms.
Kang has served as our Chief Financial Officer ("CFO") since July 2021. Kang Liping was employed by Inner Mongolia Tiantai
Technology Co., Ltd from 2020 to 2021 and served as accounting supervisor. From 2006 to 2016, Ms. Kang was employed by Inner Mongolia
Guanhong Century Electronic Technology Co., Ltd. and served as accounting supervisor. Between 2017 to 2020, Ms. Kang served as accounting
supervisor at Inner Mongolia Tiantai Technology Co., Ltd. Ms. Kang was awarded a bachelor's degree with a major in Accounting by
Inner Mongolia University of Technology in 2005.

 There
are no family relationships among any of our directors or executive officers.

 Our
directors hold office until the next annual general meeting of our shareholders or until removed from office in accordance with our bylaws.
Our officers are appointed by our board of directors and hold office until resignation or removal by the board.

 Legal
Proceedings Involving Officers and Directors

 To
our knowledge, during the last ten years, none of our directors and executive officers (including those of our subsidiaries) has:

 Had
a bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the
time of the bankruptcy or within two years prior to that time.

 Been
convicted in a criminal proceeding or been subject to a pending criminal proceeding, excluding traffic violations and other minor offenses.

 Been
subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently
or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities.

 Been found by a court of
 competent jurisdiction (in a civil action), the SEC, or the Commodities Futures Trading Commission to have violated a federal or
 state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

 Been the subject of, or
 a party to, any sanction or order, not subsequently reverse, suspended or vacated, of any self-regulatory organization, any registered
 entity, or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons
 associated with a member.

 Board
Committees

 Audit
Committee

 On
November 30, 2023 the Board of Directors adopted the "Charter of the Audit Committee of the Board of Directors of Longduoduo Company
Limited." Shan Bo, Wu Binbin and Ma Jiayang are the members of the Audit Committee. They are each an independent director. The
Board of Directors has determined that Shan Bo is an audit committee financial expert, as defined in the Rules of the SEC, by reason
of his experience as a public accountant in connection with financial statements prepared pursuant to accounting principles generally
accepted in the United States.

 Compensation
Committee

 On
November 30, 2023 the Board of Directors adopted the "Charter of the Compensation Committee of the Board of Directors of Longduoduo
Company Limited." Our compensation committee reviews and recommends policies, practices and procedures relating to compensation
for our directors and officers and advises and consults with our officers regarding the compensation of managerial personnel and its
relation to corporate development. Wu Binbin, Xu Huibo and Ma Jiayang are the members of the Compensation Committee. Wu Binbin and Ma
Jiayang are each an independent director. Wu Binbin serves as the Chairman of the Compensation Committee.

 Nominating
Committee

 On
November 30, 2023 the Board of Directors adopted the "Charter of the Nominating and Corporate Governance Committee of the Board
of Directors of Longduoduo Company Limited." Our nominating and corporate governance committee evaluates the composition, size
and governance of our Board of Directors and its committees, evaluates and recommends candidates for election to our Board of Directors,
establishes a policy for considering stockholder nominees and reviewing our corporate governance principles and provides recommendations
to the Board of Directors. Ma Jiayang, Wu Binbin and Shan Bo are the members of the Nominating and Corporate Governance Committee. They
are each an independent director. Ma Jiayang serves as the Chairman of the Compensation Committee.

 Code
of Ethics

 On
November 30, 2023 the Board of Directors adopted the "Code of Business Conduct and Ethics." The Code is applicable to all
officers, directors and employees of the Company. A copy of the Code of Business Conduct and Ethics is filed as an exhibit to this Report.

 Section
16(a) Beneficial Ownership Reports Compliance

 Under
U.S. securities laws, commencing on November 27, 2023 when we registered our common stock with the SEC, directors, certain officers and
persons holding more than 10% of our common stock must report their initial ownership of our common stock and any changes in their ownership
to the SEC. The SEC has designated specific due dates for these reports and we must identify in this Annual Report on Form 10-K those
persons who did not file these reports when due. To our knowledge, based solely on our review of copies of the reports filed with the
SEC, we believe that all reporting requirements for fiscal year 2025 were complied with by each person who at any time during the 2025
fiscal year was a director or an executive officer or held more than 10% of our common stock,

 Item
11. Executive Compensation.

 Summary
Compensation Table

 The
following table sets forth all compensation awarded to, earned by, or paid by Longduoduo or its subsidiaries to its Chairman of the Board,
Chief Executive Officer and Chief Financial Officer during the past two fiscal years. There was no officer or employee whose compensation
for fiscal year 2025 exceeded $100,000.

 Non-

Equity

 Non-

qualified

 Incentive

 Deferred

 All

 Year
 Ended

 Salary

 Bonus

 Stock
 Awards

 Option
 Awards

 Plan
 Comp.

 Comp.
 Earnings

 Other
 Comp.

 Total

 Name
 and Principal Position

 June 30

 ($)*

 ($)

 ($)

 ($)

 ($)

 ($)

 ($)

 ($)

 Xu Huibo

 2025

 36,046

 -

 -

 -

 -

 -

 -

 36,046

 Chairman of the Board

 2024

 41,784

 -

 -

 -

 -

 -

 -

 41,784

 2025

 22,245

 -

 -

 -

 -

 -

 -

 22,245

 CEO

 2024

 38,218

 -

 -

 -

 -

 -

 -

 38,218

 2025

 21,921

 -

 -

 -

 -

 -

 -

 21,921

 CFO

 2024

 19,646

 -

 -

 -

 -

 -

 -

 19,646

 Outstanding
Equity Awards

 There
were no unexercised options, stock that has not vested, or equity incentive plan awards for any officer or employee as of June 30, 2025
or 2024, respectively.

 Employment
Contracts, Termination of Employment, Change-in-Control Arrangements

 We
have entered into employment contracts with our executive officers under the term of salary disclosed on the summary compensation table.
Each party to the contract may terminate the contract upon thirty days prior written notice. We have not entered into any other arrangements
with our executive officers. There are no compensation plans or arrangements, including payments to be made by us, with respect to our
officers, directors or consultants that would result from the resignation, retirement or any other termination of such directors, officers
or consultants from us. There are no compensation arrangements for directors, officers, employees or consultants that would result from
a change-in-control.

 Compensation
of Directors

 We
have no formal plan for compensating our directors for their services in their capacity as directors. Directors are entitled to reimbursement
for reasonable travel and other out-of-pocket expenses incurred in connection with attendance at meetings of our Board of Directors.
The Board of Directors may award special remuneration to any director undertaking any special services on behalf of the Company other
than services ordinarily required of a director. To date, we have paid no compensation to any person for services as a member of the
Company's Board of Directors.

 Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 The
following table sets forth information regarding the beneficial ownership of our common stock for (1) each person, or group of affiliated
persons, known by us to beneficially own more than 5% of our common stock; (2) each of our named executive officers; (3) each of our
directors; and (4) all of our executive officers and directors as a group.

 We
have determined beneficial ownership in accordance with the rules of the Securities and Exchange Commission. These rules generally attribute
beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities.
The person is also deemed to be a beneficial owner of any security of which that person has a right to acquire beneficial ownership within
60 days. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect
to all shares shown as beneficially owned by them, subject to applicable community property laws. The address for each person listed
in the table is c/o Longduoduo, G3-5-8016 Shui'an Town, Ruyi Headquarters Base, Hohhot Economic Development Zone, Inner Mongolia.

 The
percentage ownership information shown in the table below is calculated based on 30,015,036 shares of our common stock issued and outstanding
as of the date of this report. We do not have any outstanding options, warrants or other securities exercisable for or convertible into
shares of our common stock.

 Executive Officers and Directors

 Amount of
 Beneficial
 Ownership of
 Common
 Stock (1)

 Percentage
 Ownership of
 Common
 Stock

 Directors and Named Executive Officers:

 Xu Huibo

 106,036

 0.35
 %

 Shan Bo

 -

 -
 %

 -

 -
 %

 Wu Binbin

 -

 -
 %

 Ma Jiayang

 -

 -
 %

 5,017

 0.02
 %

 -

 -

 All executive officers and directors as a group (6 persons)

 111,053

 0.37
 %

 5% or Greater Shareholders

 Zhang Liang

 15,397,680

 51.30
 %

 Li Qiaozhen

 1,596,034

 5.32
 %

 Liu Jiazhong

 1,527,700

 5.09
 %

 Guo Xiaozhen

 1,677,234

 5.59
 %

 (1)

 Beneficial ownership is
 determined in accordance with the rules of the SEC and includes voting or investment power with respect to the common stock. All
 shares represent only common stock held by shareholders as no options are issued or outstanding.

 We
are not aware of any contract or other arrangement the operation of which may at a subsequent date result in a change in control of our
Company.

 Item
13. Certain Relationships and Related Transactions, and Director Independence.

 There
was no transaction in which a related person had a material interest during the past fiscal year nor any currently proposed transaction,
in which the amount involved exceeded the lesser of $120,000 or one percent of our average total assets at the end of the two most recent
fiscal years.

Independence

 The
Company's Board of Directors has determined that Shan Bo, Wu Binbin and Ma Jiayang are independent directors, as "independence"
is defined in the Rules of the NYSE American.

 Item
14. Principal Accounting Fees and Services.

 Bush
& Associates CPA LLC was engaged to serve as the Company's independent registered public accounting firm on August 12, 2024.

 The
following table shows the fees that were billed for the audit and other services provided by Bush & Associates CPA LLC with respect
to the fiscal year ended June 30, 2025 and 2024.

 Year
 Ended June 30,

 2025

 2024

 Audit fees

 $

 135,000

 $

 128,000

 Audit-related fees

 $

 $

 Tax fees

 $

 $

 All other fees

 $

 $

 Our
Board of Directors pre-approves all audit and non-audit services performed by the Company's auditor and the fees to be paid in
connection with such services.

 PART
IV

 ITEM
15. EXHIBITS, FINANCIAL STATEMENTS SCHEDULES

TO EXHIBITS

 Exhibit
 No.

 Description
 of Exhibit

 3.1(a)

 Articles
 of Incorporation of Registrant (1)

 3.1(b)

 Certificate of
 Change Pursuant to NRS 78.209 filed on September 21, 2023 (2)

 3.2

 Bylaws
 of Registrant (1)

 4(iv)

 Description
 of Common Stock(3)

 10.1

 Form
 of Sales Agency Agreement, dated June 20, 2023 and expiring on June 20, 2026 by and between (a) Longduoduo Health Technology Co.,
 Ltd. and Inner Mongolia Honghai Health Management Co., Ltd. ("Honghai"), (b) Inner Mongolia Rongbin Health Consulting
 Co., Ltd. and Honghai, (c) Inner Mongolia Chengheng Health Consulting Co., Ltd. and Honghai, (d) Inner Mongolia Qinguo Health Consulting
 Co., Ltd. and Honghai, and (e) Inner Mongolia Tianju Health Consulting Company Limited and Honghai. (4)

 Code
 of Business Conduct and Ethics (4)

 21.1

 List of Company Subsidiaries

 31.1

 Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 31.2

 Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 32.1

 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 32.2

 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 101.INS

 101.SCH

 Schema Document

 101.CAL

 Calculation Linkbase Document

 101.DEF

 Definition Linkbase Document

 101.LAB

 Label Linkbase Document

 101.PRE

 Presentation Linkbase Document

 Cover Page Interactive

 (1)

 Incorporated by reference
 to the Exhibits to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on November 10, 2021.

 (2)

 Incorporated by reference
 to the Exhibits to the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 27, 2023.

 (3)

 Incorporated by reference
 to the description of the common stock contained in the Company's Registration Statement on Form 8-A filed on November 27,
 2023

 (4)

 Incorporated by reference
 to the Exhibits to the Annual Report on Form 10-K for the year ended June 30, 2024 filed on October 15, 2024.

 Item
16. FORM 10-K SUMMARY

 None.

 SIGNATURES

 In
accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

COMPANY LIMITED

 Signature

 Title

 Date

 /s/

 Chief
 Executive Officer

 September
 26, 2025

 (Principal Executive Officer)

 /s/

 Chief
 Financial Officer

 September
 26, 2025

 (Principal Financial and
 Accounting Officer)

 In
accordance with the Exchange Act, this Report has been signed below on September 26, 2025 by the following persons, on behalf of the
Registrant and in the capacities and on the dates indicated.

 Signature

 Title

 /s/

 Chief Executive Officer;

 /s/

 Chief Financial Officer

 /s/
 Xu Huibo

 Xu Huibo

 /s/
 Wu Binbin

 Wu Binbin

 /s/
 Shan Bo

 Shan Bo

 /s/
 Ma Jiayang

 Ma Jiayang

 0001892316 false FY true

 2024-12-31

 2025-09-26

 us-gaap: RelatedPartyMember

 us-gaap: RelatedPartyMember

 lddc: ServiceRevenueMember

 lddc: ServiceRevenueMember

 lddc: CommissionRevenueMember

 lddc: CommissionRevenueMember

 lddc: CostOfServiceRevenueMember

 lddc: CostOfServiceRevenueMember

 lddc: LongduoduoCompanyLimitedMember

 2021-10-26
 2021-10-26

 lddc: LongduoduoCompanyLimitedMember

 2021-10-26

 lddc: LDDTechnologyLimitedMember

 lddc: LDDTechnologyLimitedMember

 lddc: LDDJKHongKongLimitedMember

 2024-04-09

 lddc: BeijingJulongHealthConsultingCoLimitedJulongMember

 2024-07-23

 lddc: BeijingYihuaHealthConsultingCoLimitedYihuaMember

 2025-01-07

 lddc: LongduoduoHealthTechnologyCompanyLimitedMember

 2021-08-16

 lddc: LongduoduoHealthTechnologyCompanyLimitedMember

 2025-04-02

 lddc: InnerMongoliaQingguoHealthConsultingCompanyLimitedMember

 2020-09-08

 lddc: InnerMongoliaRongbinHealthConsultingCompanyLimitedMember

 2021-03-18

 lddc: InnerMongoliaChenghengHealthConsultingCompanyLimitedMember

 2021-04-09

 lddc: InnerMongoliaTianjuHealthConsultingCompanyLimitedMember

 2021-07-05

 lddc: LongduoduoCompanyLimitedMember

 lddc: LongduoduoCompanyLimitedMember

 lddc: LDDTechnologyLimitedMember

 lddc: LDDTechnologyLimitedMember

 lddc: LDDJKHongKongLimitedMember

 lddc: LDDJKHongKongLimitedMember

 lddc: BeijingJulongHealthConsultingCoLimitedJulongMember

 lddc: BeijingJulongHealthConsultingCoLimitedJulongMember

 lddc: BeijingYihuaHealthConsultingCoLimitedYihuaMember

 lddc: BeijingYihuaHealthConsultingCoLimitedYihuaMember

 lddc: LongduoduoHealthTechnologyCompanyLimitedMember

 lddc: LongduoduoHealthTechnologyCompanyLimitedMember

 lddc: InnerMongoliaQingguoHealthConsultingCompanyLimitedMember

 lddc: InnerMongoliaQingguoHealthConsultingCompanyLimitedMember

 lddc: InnerMongoliaRongbinHealthConsultingCompanyLimitedMember

 lddc: InnerMongoliaRongbinHealthConsultingCompanyLimitedMember

 lddc: InnerMongoliaChenghengHealthConsultingCompanyLimitedMember

 lddc: InnerMongoliaChenghengHealthConsultingCompanyLimitedMember

 lddc: InnerMongoliaTianjuHealthConsultingCompanyLimitedMember

 lddc: InnerMongoliaTianjuHealthConsultingCompanyLimitedMember

 currency: CNY
 lddc: AssetsAndLiabilitiesMember

 currency: USD
 lddc: AssetsAndLiabilitiesMember

 currency: CNY
 lddc: AssetsAndLiabilitiesMember

 currency: USD
 lddc: AssetsAndLiabilitiesMember

 currency: CNY
 lddc: RevenueAndExpensesMember

 currency: USD
 lddc: RevenueAndExpensesMember

 currency: CNY
 lddc: RevenueAndExpensesMember

 currency: USD
 lddc: RevenueAndExpensesMember

 lddc: SupplierAMember

 lddc: SupplierAMember

 lddc: SupplierBMember

 lddc: SupplierBMember

 lddc: SupplierCMember

 lddc: SupplierCMember

 us-gaap: OfficeEquipmentMember

 srt: MinimumMember
 us-gaap: LeaseholdImprovementsMember

 srt: MaximumMember
 us-gaap: LeaseholdImprovementsMember

 us-gaap: ComputerSoftwareIntangibleAssetMember

 us-gaap: OfficeEquipmentMember

 us-gaap: LeaseholdImprovementsMember

 us-gaap: LeaseholdImprovementsMember

 lddc: MrZhangLiangMember

 2023-11-29
 2023-11-29

 lddc: ZhangLiangMember

 lddc: ZhangLiangMember

 lddc: ZhangLiangMember

 lddc: ZhangLiangMember

 country: US

 country: HK
 lddc: TaxYear20192020Member

 country: CN

 country: CN

 country: CN

 country: CN

 country: US

 us-gaap: DomesticCountryMember

 us-gaap: DomesticCountryMember

 us-gaap: StateAdministrationOfTaxationChinaMember

 us-gaap: StateAdministrationOfTaxationChinaMember

 lddc: USFederalMember

 lddc: TianjuMember

 2024-04-01

 lddc: TianjuMember

 2024-04-01
 2024-04-01

 lddc: MongoliaChuangfuhuiEnterpriseManagementCoLtdMember

 2024-08-14

 lddc: MongoliaChuangfuhuiEnterpriseManagementCoLtdMember

 2024-08-14
 2024-08-14

 lddc: ChenMingyueMember

 2025-09-19
 2025-09-19

 lddc: ChenMingyueMember

 2025-09-19

 lddc: ChenghengMember

 2024-11-20

 lddc: ChenghengMember

 2024-11-20
 2024-11-20

 lddc: LongduoduoHealthTechnologyMember

 2024-03-11

 lddc: LongduoduoHealthTechnologyMember

 2025-03-11
 2025-03-11

 srt: MinimumMember

 srt: MaximumMember

 srt: MinimumMember
 lddc: BorrowingRateMember

 lddc: LongduoduoMember

 lddc: QingguoMember

 lddc: ChenghengMember

 lddc: RongbinMember

 lddc: TianjuMember

 utr:sqm